P2 - Poster Session II
Event Time: | Monday April 23, 2018 11:30 am to 7:00 pm |
Topic(s): | Aging, Dementia, Cognitive, and Behavioral Neurology, Cerebrovascular Disease and Interventional Neurology, Child Neurology and Developmental Neurology, Epilepsy/Clinical Neurophysiology (EEG), Movement Disorders, MS and CNS Inflammatory Disease, Neuromuscular and Clinical Neurophysiology (EMG), Neuro-ophthalmology/Neuro-otology, Pain and Palliative Care, Research Methodology, Education, and History |
Director(s): | |
Description: | A series of thematic abstract presentations in poster format presented Sunday through Friday with evening stand-by times for authors. The specific stand-by time for this session is 5:30 p.m. to 7:00 p.m. |
Completion Message: | |
CME Credits: | 0 |
Core Competencies: |
Start/End Time | Title | Faculty |
---|---|---|
11:45 AM - 11:50 AM | P2.027 | Faculty |
11:50 AM - 11:55 AM | P2.028 | Faculty |
11:55 AM - 12:00 PM | P2.029 | Faculty |
12:00 PM - 12:05 PM | P2.030 | Faculty |
12:05 PM - 12:10 PM | P2.031 | Faculty |
12:10 PM - 12:15 PM | P2.032 | Faculty |
12:15 PM - 12:20 PM | P2.033 | Faculty |
12:20 PM - 12:25 PM | P2.034 | Faculty |
12:25 PM - 12:30 PM | P2.035 | Faculty |
12:30 PM - 12:35 PM | P2.036 | Faculty |
5:30 PM - 7:00 PM | Poster Author Standby Time | Faculty |
Speaker | Disclosure |
---|
Undergraduate Medical Education: Assessment and Curricular Design I | |||
---|---|---|---|
Start Time | Pub. | Title | Presenter |
5:30 PM | 001 | Common difficulties medical students have with the neurological physical exam are identified by direct observation. |
Juliana Coleman, MD Disclosure: Dr. Coleman has nothing to disclose.
|
5:30 PM | 002 | Evaluation of a Single Year Competency-Based Clerkship Alternative to Effectively Navigate a Fourth-Year to Third Year Curricular Transition |
Jeff Kraakevik, MD Disclosure: Dr. Kraakevik has nothing to disclose.
|
5:30 PM | 003 | Developing a Student-Centric/Student Responsive Four Week Neurology Clerkship |
Raghav Govindarajan, MD, FAAN Disclosure: Dr. Govindarajan has nothing to disclose.
|
5:30 PM | 004 | Published Headache OSCEs Have Excellent Inter-rater Reliability |
Maryam Shakir, MPH Disclosure: Dr. Shakir has nothing to disclose.
|
5:30 PM | 005 | Why aren't you giving feedback? |
Doris Kung, DO Disclosure: Dr. Kung has nothing to disclose.
|
Undergraduate Medical Education: Novel Formats | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 006 | Movement Disorders Video Curriculum for Neurology Clerkships and Residency Programs |
Sagari Bette, MD Disclosure: Dr. Bette has nothing to disclose.
|
5:30 PM | 007 | Assessment Of The Difficult Components Of Neurological Exam Performance In Medical Students |
Yi Li, MD Disclosure: Dr. Li has nothing to disclose.
|
5:30 PM | 008 | Animated Neurological Exam Videos in PBL Cases |
J. Douglas Miles, MD, PhD Disclosure: Dr. Miles has nothing to disclose.
|
5:30 PM | 009 | Student Neurology Clerkship Improvement Project ("SNIP") |
Victoria Cannon, MD Disclosure: Dr. Cannon has nothing to disclose.
|
5:30 PM | 010 | Incorporating Formal Nutrition Education into a Medical School Curriculum: A Student-Initiated Lecture Series |
Vanessa Baute, MD Disclosure: Dr. Baute has nothing to disclose.
|
5:30 PM | 011 | Expert Patient Tutors: The Eradication of Neurophobia |
Gina Hadley, MD Disclosure: Dr. Hadley has nothing to disclose.
|
Health Services Research and Methodologies | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 012 | Common Data Elements (CDEs) for Biomechanical Devices used in Blunt Head Impact and Blast Exposure Dynamics: The National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and Department of Defense (DOD) Version 1.0 Recommendations |
Kristen Joseph, MA Disclosure: Dr. Joseph has nothing to disclose.
|
5:30 PM | 013 | Development of diagnostic criteria to facilitate research in mitochondrial disorders: a proposal from the North American Mitochondrial Disease Consortium. |
Valentina Emmanuele, MD Disclosure: Dr. Emmanuele has nothing to disclose.
|
5:30 PM | 014 | Streamlining Clinical Research in Sports-Related Concussion: The National Institute of Neurological Disorders and Stroke (NINDS)/National Institutes of Health (NIH), and Department of Defense (DOD) Sport-Related Concussion Common Data Elements (CDEs) |
Kristen Joseph, MA Disclosure: Dr. Joseph has nothing to disclose.
|
5:30 PM | 015 | Registration status of clinical trials published in core neurology journals: a cross-sectional study |
Jose Merino, MD, MPhil, FAAN Disclosure: Dr. Merino has received personal compensation in an editorial capacity for the BMJ as a research editor.
|
5:30 PM | 016 | A Common Language for Clinical Research Studies: The National Institute of Neurological Disorders and Stroke (NINDS) and Centers for Disease Control and Prevention (CDC) Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Common Data Elements (CDEs) |
Robin Feldman Disclosure: Dr. Feldman has nothing to disclose.
|
Education: Career Choice and Attitudes | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 017 | Headache interest in US academic neurology leadership: a cross-sectional study |
Matthew Robbins, MD, FAAN Disclosure: Dr. Robbins has received personal compensation in an editorial capacity for Springer (Current Pain and Headache Reports). Dr. Robbins has received research support from eNeura (clinical trial; funds to institution).
|
5:30 PM | 018 | Neurology Residency Websites: A Critical Evaluation. |
Adeel Memon Disclosure: Dr. Memon has nothing to disclose.
|
5:30 PM | 019 | The Rutgers-NJMS Experience: Why Are Our Medical Students Increasingly Applying to Adult Neurology? |
Jessy Walia, MBBS Disclosure: Dr. Walia has nothing to disclose.
|
5:30 PM | 020 | Changing the Image of Neurology |
Yolanda Reyes-Iglesias, MD Disclosure: Dr. Reyes-Iglesias has nothing to disclose.
|
5:30 PM | 021 | The Importance of Neurology as a Required Third-Year Clerkship: a Medical Student Survey |
Enmanuel Perez Disclosure: Dr. Perez has nothing to disclose.
|
5:30 PM | 022 | The Impact of Early Medical School Exposure to Clinical Neurology on Career Interest in Neurology |
Yasmin Aghajan Disclosure: Dr. Aghajan has nothing to disclose.
|
5:30 PM | 023 | NA |
NA NA Disclosure:
|
5:30 PM | 024 | NA |
NA NA Disclosure:
|
5:30 PM | 025 | NA |
NA NA Disclosure:
|
5:30 PM | 026 | NA |
NA NA Disclosure:
|
Neuromuscular and Clinical Neurophysiology (EMG) Poster Discussion Session | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 027 | Machine-learning in neurodegeneration: evaluation, optimisation and validation of MRI-based diagnostic methods |
Peter Bede, MD Disclosure: Dr. Bede has nothing to disclose.
|
5:30 PM | 028 | Skeletal Muscle Interstitial Amyloid in Anoctaminopathy-5: Does it Matter? |
Charenya Anandan, MD Disclosure: Dr. Anandan has nothing to disclose.
|
5:30 PM | 029 | Egr2-dependent microRNA-138 is Dispensable for Peripheral Nerve Myelination |
Hsin-Pin Lin Disclosure: Dr. Lin has nothing to disclose.
|
5:30 PM | 030 | The Long Exercise Test in Primary Periodic Paralysis: a Bayesian Analysis |
Daniel Simmons, MD Disclosure: Dr. Simmons has nothing to disclose.
|
5:30 PM | 031 | Congenital Myasthenic Syndromes (CMS) Due to Impaired Principal Coupling Pathway in the ? Subunit of Muscle Acetylcholine Receptor (AChR) |
Xin-Ming Shen, PhD Disclosure: Dr. Shen has nothing to disclose.
|
5:30 PM | 032 | Integrated MRI and [11C]-PBR28 PET Imaging to Characterize In vivo Glial Activation in Amyotrophic and Primary Lateral Sclerosis: Cross Sectional and Longitudinal Study |
Mohamad Alshikho Disclosure: Dr. Alshikho has nothing to disclose.
|
5:30 PM | 033 | Undiagnosed Congenital Myasthenic Syndromes in Adult Neuromuscular Practice: a Long Road to Diagnosis and Treatment. |
Justin Kao, MBChB Disclosure: Dr. Kao has nothing to disclose.
|
5:30 PM | 034 | ALS progression over short time intervals: early insights from the ongoing ALS-at-home study |
Seward Rutkove, MD Disclosure: Dr. Rutkove has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Myolex, Biogen, Axcella Health, and Merck. Dr. Rutkove has received personal compensation in an editorial capacity for Annals of Neurology. Dr. Rutkove has received compensation for serving on the Board of Directors of Myolex, Inc.. Dr. Rutkove holds stock and/or stock options in Myolex, Inc.. Dr. Rutkove has received research support from Flex-Pharma, Inc..
|
5:30 PM | 035 | Efficacy of Dichlorphenamide in Primary Periodic Paralysis: Pooled-Data Analysis of Two Phase 3 Clinical Trials |
Perry Shieh, MD, PhD Disclosure: Dr. Shieh has nothing to disclose.
|
5:30 PM | 036 | Decreased EEG Spectral Power and Increased Cortico-Cortical Connectivity Correlate with Structural MRI Changes in Amyotrophic Lateral Sclerosis |
Stefan Dukic Disclosure: Dr. Dukic has nothing to disclose.
|
Parkinson's Disease: Therapeutics | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 037 | Effects of Probiotics on Constipation, Neurological Symptoms, and Quality of Life Associated with Parkinson's Disease |
Duarte Machado, MD Disclosure: Dr. Machado has nothing to disclose.
|
5:30 PM | 038 | Exploratory risk analysis for motor complications and non-motor symptoms: observations in a registry of a tertiary Parkinson's disease center in Brasilia, Brazil |
Talyta Grippe, MD Disclosure: Dr. Grippe has nothing to disclose.
|
5:30 PM | 039 | A Phase 2 study of Isradipine as a disease modifying agent in patients with early Parkinson's disease (STEADY-PD III): Baseline characteristics and study update |
Tanya Simuni, MD Disclosure: Dr. Simuni has nothing to disclose.
|
5:30 PM | 040 | Optimizing Delivery of Carbidopa/Levodopa via the Accordion Pill™: Comparative PK and Safety From 2 Randomized Crossover Studies in Healthy Volunteers |
Nadav Navon Disclosure: Dr. Navon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Intec LTD Jerusalem.
|
5:30 PM | 041 | Objective Evaluation of Levodopa Response on Gait and Balance |
Alexandra Fowler Disclosure: Dr. Fowler has nothing to disclose.
|
5:30 PM | 042 | Effect of PD medication on disease progression as measured by rate of change in MDS_UPDRS in PPMI study |
Zhen Xiao, PhD Disclosure: Dr. Xiao has nothing to disclose.
|
5:30 PM | 043 | Pharmacokinetics of ADS-5102 (amantadine) Extended Release Capsules Administered Once-Daily at Bedtime for the Treatment of Dyskinesia |
Robert Hauser, MD, MBA, FAAN Disclosure: Dr. Hauser has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities. Dr. Hauser reports receiving licensing fee payments from the University of South Florida. Dr. Hauser has received research support from Abbvie Pharmaceutical Research and Development, Astra Zeneca, Axovant, Biotie Therapies, Acorda/Civitas Therapeutics, Inc, Axovant, Biogen, Biotie, Enterin, Cynapsus/Sunovion, Intec, Impax Pharmaceuticals, Kyowa Kirin Pharmaceuticals, Jazz Pharmaceuticals, Lundbeck, Neuroderm, Pfizer, PPMI (MJFF), and Hoffman - La Roche.
|
5:30 PM | 044 | The iNDiGO study: A multicenter, randomized, double-blind, placebo-controlled clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in fluctuating PD |
Karl Kieburtz, MD, FAAN Disclosure: Dr. Kieburtz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with the National Institutes of Health, the Michael J. Fox Foundation, Medivation, Neurosearch, the United States Food and Drug Administration, Veterans Administration, AbbVie, and Acorda.
|
5:30 PM | 045 | A Phase 3 Study of Tozadenant (TOZ-PD) as a Maintenance Therapy for Patients With Parkinson's Disease Experiencing Motor Fluctuations: Characterization of Study Population |
Karl Kieburtz Disclosure: Dr. Kieburtz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with the National Institutes of Health, the Michael J. Fox Foundation, Medivation, Neurosearch, the United States Food and Drug Administration, Veterans Administration, AbbVie, and Acorda.
|
5:30 PM | 046 | Safety and Efficacy of Levodopa-Carbidopa Monotherapy in Patients with Advanced Parkinson's Disease |
James Boyd, MD Disclosure: Dr. Boyd has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc., Teva, Lundbeck, Chrono Therapeutics, Neurocrine and Medical Education Resources. Dr. Boyd has received research support from Michael J. Fox Foundation, NIH/NINDS, Auspex, Biotie, CHDI Foundation, NeuroDerm, Chrono Therapeutics, Vaccinex, AbbVie Inc.
|
5:30 PM | 047 | Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Advanced Parkinson's Disease Patients Receiving ≥ 2000 mg Daily Dose of Levodopa |
Cindy Zadikoff, MD Disclosure: Dr. Zadikoff has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, USworldMeds, Acadia, UCB, St Jude, Merz, Teva, and Lundbeck. Dr. Zadikoff holds stock and/or stock options in Dial N Doc. Dr. Zadikoff has received research support from AbbVie, Allergan, St Jude for unrestricted educational grants.
|
5:30 PM | 048 | Rationale and Design of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson's Disease - INSIGHTS Study |
K. Ray Chaudhuri Disclosure: Dr. Chaudhuri has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc., Voyager Therapeutics, and Serina Therapeutics. Dr. Chaudhuri has received research support from AbbVie Inc.
|
Parkinson's Disease: Phenomenology, Epidemiology and Rating Scales | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 049 | Dry facts are not always inviting: an analysis of Korean videos about Parkinson's disease on YouTube |
Beomseok Jeon, MD Disclosure: Dr. Jeon has nothing to disclose.
|
5:30 PM | 050 | Clinical factors associated with clinician certainty in diagnosis of idiopathic Parkinson's disease |
Kishan Ughreja, BA Disclosure: Dr. Ughreja has nothing to disclose.
|
5:30 PM | 051 | Item Response Theory Analysis of the Unified Dyskinesia Rating Scale Items |
Christopher Goetz, MD, FAAN Disclosure: Dr. Goetz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Boston Scientific, the International Parkinson and Movement Disorder Society, Cray-Huber Attorneys and the University of Pittsburgh. Dr. Goetz is employed by Rush University Medical Center. Dr. Goetz has received (royalty or license fee or contractual rights) payments from Elsevier Publishers, Oxford University Press and Wolters Kluwer. Dr. Goetz has received research support from NIH, the Michael J. Fox Foundation, the Parkinson's Disease Foundation and the International Parkinson and Movement Disorder Society (IPMDS).
|
5:30 PM | 052 | A Clinically Important Difference (CID) for the Unified Dyskinesia Rating Scale (UDysRS) Total Score Change in Parkinson's Disease (PD) Patients with Dyskinesia |
Rajesh Pahwa, MD, FAAN Disclosure: Dr. Pahwa has received consulting fees from Abbvie, ACADIA, Acorda, Adamas, Cynapses, Global Kinetics, Lundbeck, Neurocrine, Pfizer, Sage, Sunovion, Teva Neuroscience, and US World Meds. Dr. Pahwa has received personal compensation in an editorial capacity as the Co-Editor-In-Chief of the International Journal of Neuroscience. Dr. Pahwa has received research support from Abbvie, Adamas, Avid, Biotie, Boston Scientific, Cala Health, Civitas, Cynapses, Kyowa, National Parkinson Foundation, NIH/NINDS, Parkinson Study Group, and Pfizer.
|
5:30 PM | 053 | Smoking and Coffee Consumption Preceding Clinically-diagnosed Synucleinopathies: A Case-control Study in Olmsted County MN (1991-2005). |
Jinna Yu Disclosure: Dr. Yu has nothing to disclose.
|
5:30 PM | 054 | Predictors of Disability in Parkinson Disease: Motor vs. Cognitive Impairment Using MMSE vs. MoCA |
Allison Snyder, MD Disclosure: Dr. Snyder has nothing to disclose.
|
5:30 PM | 055 | Communication Regarding Off Time with People with Parkinsons and their Caregivers: Qualitative Analysis of Physician Interviews |
Tara Rastgardani, MD Disclosure: Dr. Rastgardani has nothing to disclose.
|
5:30 PM | 056 | Foundations for a Patient-Reported Natural History of Parkinson Disease: Cross-sectional Analysis of the MJFF Fox Insight (FI) Platform |
Lakshmi Arbatti Disclosure: Dr. Arbatti has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Grey Matter Technologies.
|
5:30 PM | 057 | Stumbling, Near-falls, Freezing or Postural Instability: What Predicts Falling Best in Parkinson Disease? |
Zahra Nooshin Rezvani Disclosure: Dr. Rezvani has nothing to disclose.
|
5:30 PM | 058 | Diagnostic Impact of Movement Disorders Subspecialty Consultations at a VA Hospital |
Brandon Barton, MD Disclosure: Dr. Barton has nothing to disclose.
|
5:30 PM | 059 | Levodopa-induced dyskinesias in Parkinson disease: a population based-cohort study in Olmsted County, MN (1991-2010) |
Pierpaolo Turcano, MD Disclosure: Dr. Turcano has nothing to disclose.
|
5:30 PM | 060 | A Real-World Inquiry of the So-Called Parkinsonian Personality -- Comparing No-Show Rates of the Neurology Outpatients with and without Parkinson's disease (PD) |
Jeremiah Bell, MD Disclosure: Dr. Bell has nothing to disclose.
|
5:30 PM | 061 | Parkinson's Diagnostic Accuracy- What diagnoses cause the most diagnostic-switches by Movement Disorder Specialists? |
Marzieh Keshtkarjahromi Disclosure: Dr. Keshtkarjahromi has nothing to disclose.
|
5:30 PM | 062 | Barriers to Vaccination in Homebound and Non-Homebound People with Parkinson's Disease |
Jori Fleisher, MD, MSCE Disclosure: Dr. Fleisher has nothing to disclose.
|
5:30 PM | 063 | Traumatic brain injury and erectile dysfunction preceding clinically diagnosed alpha-synucleinopathies: a case - control study in Olmsted County, MN (1991-2010). |
Shemonti Hasan Disclosure: Dr. Hasan has nothing to disclose.
|
5:30 PM | 064 | Objective Markers of Turning in Idiopathic Parkinson's Disease |
Lakshmi Pillai Disclosure: Dr. Pillai has nothing to disclose.
|
5:30 PM | 066 | Prevalence and patterns of rest, postural and action tremor in drug-naive Parkinson's disease |
Deepak Gupta, MD, MBBS Disclosure: Dr. Gupta has nothing to disclose.
|
5:30 PM | 067 | Experiences, impact, and communication of "off" periods in Parkinson's disease: qualitative experiences of patients and carepartners |
Tara Rastgardani, MD Disclosure: Dr. Rastgardani has nothing to disclose.
|
5:30 PM | 068 | Characteristics of Patients with Parkinson Disease in Pakistan: Prospective Multicenter Cross-sectional Study |
Wagma Shahzad Disclosure: Dr. Shahzad has nothing to disclose.
|
5:30 PM | 069 | Predictors of health-related quality of life in Parkinson's disease |
Gregory Kuhlman, MD Disclosure: Dr. Kuhlman has nothing to disclose.
|
5:30 PM | 070 | Prenatal Exposure to Chlorpyrifos and Parkinson's risk: a prospective adolescent cohort evaluation |
Sarah O'Shea, MD Disclosure: Dr. O'Shea has nothing to disclose.
|
5:30 PM | 071 | Primary Care Knowledge and Referral Practices Based on Early Symptoms of Parkinson's Disease |
Stephanie Bissonnette, DO Disclosure: Dr. Bissonnette has nothing to disclose.
|
5:30 PM | 072 | Characterizing Types of Falls in Parkinson's Disease |
Abraham Lieberman, MD, FAAN Disclosure: Dr. Lieberman has nothing to disclose.
|
5:30 PM | 073 | Healthcare Disparities in African-American Patients with Parkinson's Disease : A Comprehensive Literature Review and Call to Action |
Shivani Naik Disclosure: Dr. Naik has nothing to disclose.
|
5:30 PM | 074 | Deeply Phenotyped Control Cohort for Studies of Parkinson's Disease |
Rana Hanna AL-Shaikh Disclosure: Dr. Hanna AL-Shaikh has nothing to disclose.
|
5:30 PM | 075 | The Prevalence of Tandem Gait Abnormality in Parkinson's Disease |
Jason Margolesky, MD Disclosure: Dr. Margolesky has nothing to disclose.
|
5:30 PM | 076 | Instructed Arm Swing Improves Walking Performance and Decreases Fall Risk in Individuals with Parkinsonism |
Evan Fitzgerald Disclosure: Mr. Fitzgerald has nothing to disclose.
|
5:30 PM | 077 | Development of a Parkinson's Disease-Specific Admission Order Set |
Danielle Larson, MD Disclosure:
|
5:30 PM | 078 | Sex Disparities in Health and Health Care Utilization after Parkinson Diagnosis: Rethinking PD Associated Disability |
Michelle Fullard, MD Disclosure: Dr. Fullard has nothing to disclose.
|
5:30 PM | 079 | Characterization of variants in genes associated with Parkinson´s disease and parkinsonism in the African American population using exome sequencing |
Angela Deutschlander, MD Disclosure: Dr. Deutschlander has nothing to disclose.
|
5:30 PM | 080 | Presentation of Parkinson's disease in patients originating of different geographical altitudes |
Kelly Meza Capcha Disclosure: Dr. Meza Capcha has nothing to disclose.
|
5:30 PM | 081 | Differences in Quality of Life Between Men and Women with Parkinson's Disease |
Medha Gudavalli Disclosure: Dr. Gudavalli has nothing to disclose.
|
5:30 PM | 082 | Predictors of Clinically Meaningful Change in PDQ-39 in Parkinson's Disease |
Adam Margolius, MD Disclosure: Dr. Margolius has nothing to disclose.
|
5:30 PM | 083 | Use of a modified STROOP test to help with diagnosis in early idiopathic Parkinson's disease |
Rebekah Langston Disclosure: Dr. Langston has nothing to disclose.
|
5:30 PM | 084 | NA |
NA NA Disclosure:
|
Child Neurology and Developmental Neurology ePoster Session | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 085 | A splice-site mutation in USMG5 causes Leigh Syndrome due to lack of ATP synthesis |
Emanuele Barca, MD Disclosure: Dr. Barca has nothing to disclose.
|
5:30 PM | 086 | Long-term Neurodevelopmental Outcomes in Preterm Infants with Posthemorrhagic Hydrocephalus Treated with Temporizing Devices |
Lydia Bernhardt Disclosure: Dr. Bernhardt has nothing to disclose.
|
5:30 PM | 087 | Clinical profile and outcome of children with Lennox Gastaut Syndrome: Retrospective single centre cohort |
Vishal Sondhi Disclosure: Dr. Sondhi has nothing to disclose.
|
5:30 PM | 088 | Iron and ferritin levels in patients with ADHD |
Shreya Agarwal Disclosure: Dr. Agarwal has nothing to disclose.
|
5:30 PM | 089 | Unusual Presentation of Wilson Disease in a Pediatric Patient: Case Report |
Michael DiSano, MD Disclosure: Dr. DiSano has nothing to disclose.
|
5:30 PM | 090 | Striatal Changes on MRI in Young Children with NMDAR: A Single Center Experience |
Michael Nelson Disclosure: Dr. Nelson has nothing to disclose.
|
Pain and Palliative Care | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 091 | Gluten Neuropathy: Prevalence of Pain and the Role of Gluten-Free Diet. |
Panagiotis Zis, MBBS, PhD Disclosure: Dr. Zis has nothing to disclose.
|
5:30 PM | 093 | ALS Patient Perspectives on Physician Assisted Death After Recent Passage of End of Life Options Act |
Nicole Heinl Disclosure: Dr. Heinl has nothing to disclose.
|
5:30 PM | 094 | Prognostic Factors and Effectiveness of Percutaneous Balloon Compression in the Treatment of Trigeminal Neuralgia: An Experience of 222 patients |
Sergio A. F. Dantas Disclosure: Dr. Adrian Fernandes Dantas has nothing to disclose.
|
5:30 PM | 095 | Evaluation of Pain Reproduction and other Predictive Factors of Selective Lumbar Nerve Block Efficacy for the Diagnosis and Palliative Treatment of Chronic Low Back Pain: A Retrospective Cohort Study |
Yi Tong Disclosure: Dr. Tong has nothing to disclose.
|
5:30 PM | 096 | Widespread Myofascial Dysfunction and Regional Sensitization in Women with Endometriosis-associated Chronic Pelvic Pain |
Barbara Karp, MD Disclosure: Dr. Karp has received research support from Allergan and Merz.
|
5:30 PM | 098 | Botulinum Toxin Treatment of Chronic Pelvic Pain in Women with Endometriosis |
Barbara Karp, MD Disclosure: Dr. Karp has received research support from Allergan and Merz.
|
5:30 PM | 099 | Evaluation of Clinical Symptom and Signs Related to Histological and Functional Properties of Small Fiber Neuropathy in Diabetic Neuropathic Pain Patients |
ISIN UNAL-CEVIK Disclosure: Dr. UNAL-CEVIK has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer Inc.
|
5:30 PM | 100 | Polarity-specific Modulation of Central Pain Processing by Transcranial Direct Current Stimulation |
Steffen Naegel, MD Disclosure: Dr. Naegel has nothing to disclose.
|
5:30 PM | 102 | Biotin-deficiency in patients with fibromyalgia syndrome combined with small fiber pathology. |
Walter Maier-Janson, MD Disclosure: Dr. Maier-Janson has nothing to disclose.
|
5:30 PM | 103 | 'Triggers' for a Palliative Care Service for Patients with Spinocerebellar Ataxia Type 1. |
Patama Gomutbutra, MD Disclosure: Dr. Gomutbutra has nothing to disclose.
|
5:30 PM | 104 | Evaluation of Berberin- a Nrf2 Activator, on Paclitaxel-Induced Neuropathic Pain Model in Rat |
amitava chakrabarti, MD, MBBS Disclosure: Dr. Chakrabarti has nothing to disclose.
|
5:30 PM | 105 | The Effectiveness of Spinal Cord Stimulation (SCS) In Reduction of Oral Opioid Use |
Derek Yuan, MD Disclosure: Dr. Yuan has nothing to disclose.
|
5:30 PM | 106 | Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation for the Treatment of Fibromyalgia: An open label clinical trial |
Levi H. Jales Jr. Disclosure: Dr. Higino Jales Junior has nothing to disclose.
|
5:30 PM | 107 | Successful Treatment of Refractory Trigeminal Neuralgia with Sphenopalatine Ganglion Block |
Mohamed Binfalah Disclosure: Dr. Falah has nothing to disclose.
|
5:30 PM | 108 | Inflamed Brain: A Neuro-Palliative Approach |
Justin Voorhees Disclosure: Dr. Voorhees has nothing to disclose.
|
Autonomic Disorders: Autonomic Neuropathies | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 109 | Autoimmune polyneuropathy with severe dysautonomia after ipilimumab treatment for melanoma |
Kyle Kern, MD, MS Disclosure: Dr. Kern has nothing to disclose.
|
5:30 PM | 110 | A Case of Paraneoplastic Dysautonomia and Small Fiber Neuropathy |
Jacob Didion, MD Disclosure: Dr. Didion has nothing to disclose.
|
5:30 PM | 111 | Diagnostic Utility of Sweat Gland Nerve Fiber Density in Small Fiber Neuropathy |
Peter Novak, MD Disclosure: Dr. Novak has nothing to disclose.
|
5:30 PM | 112 | Dysautonomia in Charcot-Marie-Tooth Disease and Correlations with Patient-Reported Disability |
Sindhu Ramchandren, MD Disclosure: Dr. Ramchandren has nothing to disclose.
|
5:30 PM | 113 | Small Fiber Neuropathy and Multiple Endocrinopathies with COX6A1 Gene Deletion |
Glen Cook, MD Disclosure: Dr. Cook has nothing to disclose.
|
5:30 PM | 114 | Characterizing the spectrum of autonomic impairment in neurologic disorders with calcium channel antibodies |
Julie Khoury, MD Disclosure: Dr. Khoury has nothing to disclose.
|
5:30 PM | 115 | Autonomic description in patients with very early TTR amyloidosis (Familial Amyloid Polyneuropathy). |
Maria Alejandra Gonzalez Duarte, MD Disclosure: Dr. Gonzalez Duarte has nothing to disclose.
|
5:30 PM | 116 | The effect of vagal dysfunction on cytokine networks in HIV |
Elizabeth Pedowitz, MD Disclosure: Dr. Pedowitz has nothing to disclose.
|
Autonomic Disorders: Other | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 117 | Healthcare Related Costs of Autonomic Disorders in MHS Beneficiaries |
Agata Bogacki Disclosure: Dr. Bogacki has nothing to disclose.
|
5:30 PM | 118 | Progressive Multiple Sclerosis Patients Have a Higher Burden of Autonomic Dysfunction Compared to Relapsing Remitting Phenotype |
Ivan Adamec Disclosure: Dr. Adamec has nothing to disclose.
|
5:30 PM | 119 | Psychosis in Multiple System Atrophy |
Jose-Alberto Palma, MD, PhD Disclosure: Dr. Palma has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck. Dr. Palma has received personal compensation in an editorial capacity for Clinical Autonomic Research.
|
5:30 PM | 120 | Long-term Fingolimod therapy increases sympathetic cardiovascular modulation |
Ruihao Wang Disclosure: Dr. Wang has nothing to disclose.
|
5:30 PM | 121 | Cognitive impairment correlates with autonomic dysfunction in patients with a history of traumatic brain injury |
Max J. Hilz, MD, PhD, FAAN Disclosure: Dr. Hilz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme. Dr. Hilz has received personal compensation in an editorial capacity for Autonomic Neuroscience: Basic and Clinical. Dr. Hilz has received research support from Novartis Pharma GmbH.
|
5:30 PM | 122 | Seasonal Hypothermia, Hypersomnolence, Encephalopathy, and Hypoventilation Following Hypothalamus Injury - A Case of Human Hibernation? |
Leighton Mohl, MD Disclosure: Dr. Mohl has nothing to disclose.
|
5:30 PM | 123 | Three Shapiro Syndrome cases : diagnostic challenge of clinical spectrum of the spontaneous paroxysmal hypothermia syndrome |
Rubens Salomao Disclosure: Dr. Salomão has nothing to disclose.
|
5:30 PM | 124 | Autonomic Dysfunction in Patients with Down Syndrome and Alzheimer Disease |
Eric Huttler Disclosure: Dr. Huttler has nothing to disclose.
|
Autonomic Disorders: Orthostatic Hypotension and Orthostatic Intolerance | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 125 | Understanding the Symptoms of Neurogenic Orthostatic Hypotension: Results From a Survey of Patients and Caregivers |
Satish R. Raj Disclosure: Dr. Raj has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbott Laboratories, Boston Scientific Corporation, Lundbeck LLC, and GE Healthcare.
|
5:30 PM | 126 | Addressing Orthostatic Hypotension in Parkinson Disease Patients in a Neurology Resident Continuity Clinic |
Elisabeth Golden, MD Disclosure: Dr. Golden has nothing to disclose.
|
5:30 PM | 127 | Neurogenic Orthostatic Hypotension Burden of Illness Patient and Caregiver Survey: Impact of Symptoms |
Daniel O. Claassen Disclosure: Dr. Claassen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Neuroscience, Lundbeck, Acadia, and AbbVie. Dr. Claassen has received research support from NIH/NINDS, Michael J. Fox Foundation, Huntington Disease Society of America, Vaccinex, AbbVie, and Auspex Pharmaceuticals.
|
5:30 PM | 128 | Patient and Caregiver Experiences With the Diagnosis of Neurogenic Orthostatic Hypotension |
L. Arthur Hewitt Disclosure: Dr. Hewitt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck.
|
5:30 PM | 129 | Persistence of Droxidopa Treatment in Patients With Neurogenic Orthostatic Hypotension |
Jan Basile Disclosure: Dr. Basile has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Arbor Pharmaceuticals, Janssen Pharmaceuticals and Lundbeck.
|
5:30 PM | 130 | Management and Treatment of Neurogenic Orthostatic Hypotension: Results From a Survey of Patients and Caregivers |
L. Arthur Hewitt Disclosure: Dr. Hewitt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck.
|
5:30 PM | 131 | Short-Term Outcome in Children and Adolescents with Orthostatic Intolerance and Postural Tachycardia Syndrome |
Imad Jarjour, MD, FAAN Disclosure: Dr. Jarjour has nothing to disclose.
|
5:30 PM | 132 | Joint Hypermobility is Related to Pathological Finding on Tilt Table Testing |
Ivan Adamec Disclosure: Dr. Adamec has nothing to disclose.
|
5:30 PM | 133 | Running-Induced Vertigo in an Adolescent: A Treatable Orthostatic Vestibular Migraine Variant |
Imad Jarjour, MD, FAAN Disclosure: Dr. Jarjour has nothing to disclose.
|
5:30 PM | 134 | Elevated Paraneoplastic Markers: An Uncommon Finding in Orthostatic Intolerance and Postural Orthostatic Tachycardia |
Charlene Hoffman-Snyder Disclosure: Dr. Hoffman-Snyder has nothing to disclose.
|
5:30 PM | 135 | Postural Orthostatic Tachycardia: The Stanford experience |
Safwan Jaradeh, MD, FAAN Disclosure: Dr. Jaradeh has nothing to disclose.
|
Neuro-Ophthalmology/Neuro-Otology | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 136 | Isolated Sixth Cranial Nerve Palsy in Pregnancy |
Noelia García Lax Disclosure: Dr. García Lax has nothing to disclose.
|
5:30 PM | 137 | A case of optic neuropathy due to cat scratch disease (CSD) and syphilis co-infection with characteristic MRI findings |
MingYang Meah Gao, MD Disclosure: Dr. Gao has nothing to disclose.
|
5:30 PM | 138 | Wernicke's Encephalopathy After Hyperemesis Gravidarum |
Pria Anand, MD Disclosure: Dr. Anand has nothing to disclose.
|
5:30 PM | 139 | A Case of Severe Wernicke Encephalopathy with Bilateral Sensorineural Hearing Loss |
Michael Hansen Disclosure: Dr. Hansen has nothing to disclose.
|
5:30 PM | 140 | Objective Evidence of Hyper-rapid Olfactory Adaptation in Cranial Nerve I Dysfunction |
Khurram Janjua Disclosure: Dr. Janjua has nothing to disclose.
|
5:30 PM | 141 | Hypereosinophilia and Neuro-ophthalmological manifestations in Lymphoma |
Ehtesham Khalid, MBBS Disclosure: Dr. Khalid has nothing to disclose.
|
5:30 PM | 142 | Intraorbital Perineural Cyst of the Oculomotor Nerve |
Laszlo Mechtler, MD, FAAN, FASN Disclosure: Dr. Mechtler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Philips, Allergan, Supernus, Avanir and Amgen. Dr. Mechtler has received personal compensation in an editorial capacity for Springer and Elsevier. Dr. Mechtler has received compensation for serving on the Board of Directors of MEND.
|
5:30 PM | 143 | Horner's Syndrome as the Presenting Symptom in Giant Cell Arteritis |
Stephanie Figueira Disclosure: Dr. Figueira has nothing to disclose.
|
5:30 PM | 144 | Diplopia as the Presenting Symptom of Systemic T Cell Prolymphocytic Leukemia with Infiltration of the Superior Rectus Muscle. |
Humaira Khan, MD Disclosure: Dr. Khan has nothing to disclose.
|
5:30 PM | 145 | Unilateral proptosis, scleral injection and superior gaze diplopia secondary to spontaneous ophthalmic artery to superior ophthalmic vein fistula - Case report and review of literature |
Subin Mathew, MD Disclosure: Dr. Mathew has nothing to disclose.
|
5:30 PM | 146 | Development of Optic Neuritis after Vaccination, A CDC/FDA Vaccine Adverse Event Reporting System (VAERS) Study, 1990-2017. |
Janaki Patel Disclosure: Dr. Patel has nothing to disclose.
|
5:30 PM | 147 | Chronic Relapsing Inflammatory Optic Neuropathy |
Chaitanya Amrutkar, MD Disclosure: Dr. Amrutkar has nothing to disclose.
|
5:30 PM | 148 | Intravenous immunoglobulin treatment in the management of corticosteroid unresponsive optic neuritis: A retrospective case series of 15 cases |
Yu Zhao Disclosure: Dr. Zhao has nothing to disclose.
|
5:30 PM | 149 | Clinical Features and Outcomes of Pediatric Monophasic and Recurrent Idiopathic Optic Neuritis |
Soren Jonzzon Disclosure: Dr. Jonzzon has nothing to disclose.
|
5:30 PM | 150 | Audiological Profile of Multiple Sclerosis Patients in Jordan: A Case-Control Study. |
Mohammad Alkhoujah Disclosure: Dr. Alkhoujah has nothing to disclose.
|
5:30 PM | 152 | Venous Sinus Stenting Improves Visual Fields and Cerebrospinal Fluid Opening Pressures in Patients with Idiopathic Intracranial Hypertension |
Evan R Schloss, MD Disclosure: Dr. Schloss has nothing to disclose.
|
5:30 PM | 153 | Long-term Symptom Reduction of MdDS Rocking Vertigo with Theta Burst rTMS |
Benjamin Chipper Doudican Disclosure: Dr. Doudican has nothing to disclose.
|
5:30 PM | 154 | 'Sandbagging' a Vision Test for Concussion-based Sideline Assessment: An Eye Movement Investigation Objectively Reveals the 'Gamers' Strategies |
Janet Rucker, MD Disclosure: Dr. Rucker has nothing to disclose.
|
5:30 PM | 155 | Field testing the ICHD 3 beta diagnostic criteria of vestibular migraine |
Mark Obermann, MD Disclosure: Dr. Obermann has nothing to disclose.
|
5:30 PM | 156 | Psychological Measures of Individuals with Mal de Debarquement Syndrome |
Diamond Gleghorn Disclosure: Dr. Urbano has nothing to disclose.
|
5:30 PM | 157 | Vestibular Perceptual Threshold and Motion Sensitivity in Vestibular Migraine and Persistent Postural-Perceptual Dizziness |
Sebastian Wurthmann Disclosure: Dr. Wurthmann has nothing to disclose.
|
5:30 PM | 158 | Erlotinib-Induced Dandy's Syndrome: Case Report |
Kristen Steenerson, MD Disclosure: Dr. Steenerson has nothing to disclose.
|
5:30 PM | 159 | Short-Term Memory Loss in Vestibular Patients can Arise Independently of Psychiatric Impairment, Fatigue and Sleeplessness |
S.S. Surenthiran, MBBS Disclosure: Dr. Surenthiran has nothing to disclose.
|
5:30 PM | 160 | Optimal Inter-Eye Difference Thresholds in Retinal Nerve Fiber Layer and Ganglion Cell Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis: An International Collaborative Study |
Rachel Nolan Disclosure: Dr. Nolan has nothing to disclose.
|
5:30 PM | 161 | Retinal Ganglion Cell Layer and Disease Activity in Clinically Isolated Syndrome |
Hanna Zimmermann Disclosure: Dr. Zimmermann has nothing to disclose.
|
5:30 PM | 162 | Agonist of Growth Hormone Releasing Hormone (GHRH) Protects Retinal Ganglion Cells in a Model of Traumatic Optic Neuropathy |
Christian Kim Disclosure: Dr. Kim has nothing to disclose.
|
5:30 PM | 163 | Evaluation of neuroprotective properties of dimethylfumarate by optical coherence tomography in non-inflammatory models of retinal neurodegeneration |
Michael Dietrich Disclosure: Dr. Dietrich has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis.
|
5:30 PM | 164 | Mkk4 and Mkk7 are Important for Both Retinal Development and Axonal Injury-Induced Retinal Ganglion Cell Death |
Stephanie Syc Disclosure: Dr. Syc has nothing to disclose.
|
5:30 PM | 165 | Correlation of Visual Field Loss with MRI Findings in Patients with Pituitary Tumours |
Christian Lueck, MD, FAAN Disclosure: Dr. Lueck has received research support from Perpetual.
|
5:30 PM | 166 | Impact of cataract surgery on cognitive functions in elderly patients presenting to a tertiary care center in Islamabad. |
Faleha Zafar Disclosure: Dr. Zafar has nothing to disclose.
|
5:30 PM | 167 | Saccadic Intrusions Are Rare In Multiple Sclerosis |
Lisa DePledge Disclosure: Dr. DePledge has nothing to disclose.
|
5:30 PM | 168 | Correlative Enhancement: Evaluation of a new postprocessing algorithm for diagnosis of optic neuritis. |
Leanne Stunkel, MD Disclosure: Dr. Stunkel has nothing to disclose.
|
5:30 PM | 169 | The New MULES: A Sideline-Friendly Test of Rapid Picture Naming for Concussion |
Omar Akhand Disclosure: Dr. Akhand has nothing to disclose.
|
5:30 PM | 170 | NA |
NA NA Disclosure:
|
5:30 PM | 171 | NA |
NA NA Disclosure:
|
5:30 PM | 172 | NA |
NA NA Disclosure:
|
Behavioral and Cognitive Neurology: Genes, Environment, and Interventions | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 173 | Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype |
John Parker, MD Disclosure: Dr. Parker has nothing to disclose.
|
5:30 PM | 174 | Huntington's disease across four generations in a mexican family: Westphal variant with female predominance |
Jazmin Sotelo-Hernandez Disclosure: Dr. Sotelo-Hernandez has nothing to disclose.
|
5:30 PM | 175 | Fahr's disease due to a novel SLC20A2 gene mutation in a Canadian patient: Early Neurocognitive, Structural and Metabolic changes |
Leila Sellami, MD Disclosure: Dr. Sellami has nothing to disclose.
|
5:30 PM | 176 | Two Distinct Clinical Phenotypes in a Family with ALSP Caused by a Novel CSF-1R Mutation. |
Ryan Taylor, MD Disclosure: Dr. Taylor has nothing to disclose.
|
5:30 PM | 177 | A Case of AARS2 Leucoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL) |
Michael Doyle, MRCPI Disclosure: Dr. Doyle has nothing to disclose.
|
5:30 PM | 178 | Correlation Between Exercise and Motor Skills with Elderly Patients Cognition |
Cassio Henrique Taques Martins Disclosure: Dr. Martins has nothing to disclose.
|
5:30 PM | 179 | Dietary Approaches to Stop Hypertension (DASH) Diet Associated with Lower Rates of Depression |
Laurel Cherian, MD Disclosure: Dr. Cherian has nothing to disclose.
|
5:30 PM | 180 | An Exploratory Analysis of Lifetime Surgical History and Cognition |
James Bateman, MD Disclosure: Dr. Bateman has nothing to disclose.
|
5:30 PM | 181 | Neurostimulation for Functional Weakness: A Longitudinal Evaluation of Cortical Neurophysiology |
Matthew J Burke, MD Disclosure: Dr. Burke has nothing to disclose.
|
5:30 PM | 182 | 'Just Google It' – The Effect of Media Events on Patterns of Public Interest in the 'Vaccines Cause Autism' Fallacy from 2004-2017 |
Shehryar Sheikh BA Disclosure: Dr. Sheikh has nothing to disclose.
|
Genetic and Basic Science Studies in Neurodegenerative Diseases | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 183 | Characterization of Regulatory T Lymphocytes in the progression of Alzheimer's Disease |
Alirexa Faridar, MD Disclosure: Dr. Faridar has nothing to disclose.
|
5:30 PM | 184 | Age-Dependent White Matter Inflammation and Cognitive Impairment in the TgAPP21 Rat Model of Alzheimer Disease |
Alexander Levit Disclosure: Dr. Levit has nothing to disclose.
|
5:30 PM | 185 | Case Control Study of RNA Editing in Blood Reveals Decreased Global Levels of A-to-I Editing in Alzheimer's Disease |
Olivia Gardner Disclosure: Dr. Gardner has nothing to disclose.
|
5:30 PM | 186 | Genetic Basis of Motoric Cognitive Risk Syndrome in Health and Retirement Study |
Sanish Sathyan Disclosure: Dr. Sathyan has nothing to disclose.
|
5:30 PM | 187 | Familial Adult-onset Neuronal Intranuclear Inclusion Disease |
Monique Montenegro Disclosure: Dr. Montenegro has nothing to disclose.
|
5:30 PM | 188 | Amyloid-beta Induction of PIAS1 Ser-503 Phosphorylation and Elk-1 SUMOylation Mediate Endogenous Neuroprotection against Amyloid-beta Toxicity |
Shau-Yu Liu Disclosure: Dr. Liu has nothing to disclose.
|
5:30 PM | 189 | Mutational Analysis of AARS2 in Japanese Patients with Adult-Onset Leukoencephalopathy Lacking CSF1R Mutation |
Naomi Mezaki Disclosure: Dr. Mezaki has nothing to disclose.
|
5:30 PM | 190 | Identification and Functional Assay of Novel CSF1R Mutations in Patients with Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia |
Takeshi MIURA Disclosure: Dr. Miura has nothing to disclose.
|
5:30 PM | 191 | Tau-related dysfunction of BRCA1 lead to reduced neuronal plasticity in Alzheimer's disease |
Tatsuo Mano, MD, PhD Disclosure: Dr. Mano has nothing to disclose.
|
5:30 PM | 192 | Measuring the Contributions of Heritable and Non-Heritable Risk Factors to Alzheimer Disease Age-at-Symptomatic-Onset in Adult Children of Affected Parents |
Gregory Day, MD, MSc Disclosure: Dr. Day has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with DynaMed (EBSCO Health) and MedEdicus. Dr. Day holds stock and/or stock options in ANI Pharmaceuticals. Dr. Day has received research support from Avid Radiopharmaceuticals.
|
5:30 PM | 193 | Clinical and neuropsychological features of a family with a novel PSEN-1 variant (I416T) |
Laura Ramírez-Aguilar Disclosure: Dr. Ramírez-Aguilar has nothing to disclose.
|
5:30 PM | 194 | Genome-wide Association Study Based on A/T/N System Identifies New Susceptibility Loci for Alzheimer's Disease |
Chenchen Tan Disclosure: Dr. Tan has nothing to disclose.
|
5:30 PM | 195 | African Haplotypic Background Mitigates the Effect of APOE e4 Risk Allele in Alzheimer Disease |
Farid Rajabli Disclosure: Dr. Rajabli has nothing to disclose.
|
5:30 PM | 196 | TREM2 P.Arg47His Is Not Associated With Late-Onset Alzheimer's Disease In A Tunisian Population |
Mouna Ben Djebara Disclosure: Dr. Ben Djebara has nothing to disclose.
|
5:30 PM | 197 | In vitro, In vivo and cerebrospinal fluid studies implicate decreased ABCA-1 activity with APOE4 |
Varun Rawat Disclosure: Dr. Rawat has nothing to disclose.
|
5:30 PM | 198 | Case Report: SPG4-related cognitive decline in a patient with deletion of exons 5-17 |
Elizabeth Coffee Disclosure: Dr. Coffee has nothing to disclose.
|
5:30 PM | 199 | NA |
NA NA Disclosure:
|
5:30 PM | 200 | NA |
NA NA Disclosure:
|
Stroke Epidemiology, Risk Factors, and Outcomes | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 201 | Characterizing Stroke in Transgender Adults - a San Francisco General Hospital Study |
Sara LaHue, MD Disclosure: Dr. LaHue has nothing to disclose.
|
5:30 PM | 202 | The Role of Acute versus Ever Use of Cocaine in Ischemic Stroke of Young Adults |
Sleiman El Jamal, MD Disclosure: Dr. El Jamal has nothing to disclose.
|
5:30 PM | 203 | Code 420: A case series of accidental marijuana ingestion masquerading as acute stroke |
Katherine Werbaneth, MD Disclosure:
|
5:30 PM | 204 | Recreational Use Of Marijuana and Stroke: A Nationwide Outcome Study |
Urvish Patel Disclosure: Dr. Patel has nothing to disclose.
|
5:30 PM | 205 | Impact of Cocaine Use on Acute Ischemic Stroke Patients: Insights from Nationwide Inpatient Sample in the United States |
Zabeend Mahuwala, MD Disclosure: Dr. Mahuwala has nothing to disclose.
|
5:30 PM | 206 | History of Diabetes, Drug Abuse and Smoking Predicts Recurrence Rate of Ischemic Stroke in the Young |
Muhammad Ahmed, MD Disclosure: Dr. Ahmed has nothing to disclose.
|
5:30 PM | 207 | Continued Nationwide decline in Stroke related In-Hospital Mortality in United States |
Mohammad Rauf Afzal Disclosure: Dr. Afzal has nothing to disclose.
|
5:30 PM | 208 | Clinical Characteristics of Stroke Patients with Essential Thrombocytosis according to JAK2 mutation |
Joung-Ho Rha, MD, PhD Disclosure: Dr. Rha has nothing to disclose.
|
5:30 PM | 209 | Trauma due to Acute Ischemic Stroke: A Case Series |
Kevin Yeboah, MD Disclosure: Dr. Yeboah has nothing to disclose.
|
5:30 PM | 210 | Only hepatic fibrosis, not steatosis, assessed on transient elastography is an independent predictor of long-term mortality in patients with ischemic stroke. |
Minyoul Baik, MD Disclosure: Dr. Baik has nothing to disclose.
|
5:30 PM | 211 | Level of Consciousness at Discharge and Associations with Outcome After Ischemic Stroke |
Michael Reznik, MD Disclosure: Dr. Reznik has nothing to disclose.
|
5:30 PM | 212 | Aphasia at Presentation Predicts Poor Functional Outcome After Acute Ischemic Stroke |
Kathleen L. Donahue Disclosure: Dr. Donahue has nothing to disclose.
|
5:30 PM | 213 | Cancer and Stroke - Presentations and Problems |
David Collas, MD Disclosure: Dr. Collas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer and Pfizer.
|
5:30 PM | 214 | Stroke in Teens |
Chandramouleeswaran Venkatraman Disclosure: Dr. Venkatraman has nothing to disclose.
|
5:30 PM | 215 | Development and Validation of Graphical Displays for Reporting Acute Stroke Trials that Use a Patient-Centered Disability Outcome Primary Endpoint |
Ivie Tokunboh Disclosure: Dr. Tokunboh has nothing to disclose.
|
5:30 PM | 216 | Classical Crossed Medullary Syndromes in Patients with Lateral Medullary Infarction |
Guillermo Delgado-García Disclosure: Dr. Delgado-Garcia has nothing to disclose.
|
5:30 PM | 217 | Etiologies, risk factors and functional outcomes of young stroke in a Taiwanese cohort |
Chun-Yu Chen Disclosure: Dr. Chen has nothing to disclose.
|
5:30 PM | 218 | Prevalence of HIV Infection Among Stroke Patients and its Association with Mortality in Southwestern Uganda |
Amir Abdallah Disclosure: Dr. Abdallah has nothing to disclose.
|
5:30 PM | 219 | Incidence of Ischemic and Hemorrhagic Stroke Amongst Asians in the United States |
Antonio Moya, MD Disclosure: Dr. Moya has nothing to disclose.
|
5:30 PM | 220 | Leukoaraiosis & Metabolic Syndrome In Middle Age Egyption Ischemic Stroke Patients |
Wael Amer, MD Disclosure: Dr. Amer has nothing to disclose.
|
5:30 PM | 221 | Impact of Reactive Hyperglycemia on Stroke Severity and Outcome in Lagos, Nigeria |
Osigwe Agabi, MD Disclosure: Dr. Agabi has nothing to disclose.
|
5:30 PM | 222 | Predictors of Stroke Recurrence at Lagos University Teaching Hospital,Nigeria. |
Nosakhare Osemwegie Disclosure: Dr. Nosakhare has nothing to disclose.
|
5:30 PM | 223 | Clinical characteristics of borderzone infarction in Egyptian population |
Nevine EL Nahas Disclosure: Dr. EL Nahas has nothing to disclose.
|
Stroke Biomarkers and Animal Models | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 224 | Neurovascular Protective Effects of Remote Ischemic Preconditioning in Acute Ischemic Stroke Model |
Farris Taha Disclosure: Dr. Taha has nothing to disclose.
|
5:30 PM | 225 | Functional Remapping of the Mouse Somatosensory Cortex After Ischemic Stroke |
William Zeiger, MD, PhD Disclosure: Dr. Zeiger has nothing to disclose.
|
5:30 PM | 226 | Multimodal Imaging of White Matter Inflammation in a Rat Model of Striatal Ischemic Stroke |
Alexander Levit Disclosure: Dr. Levit has nothing to disclose.
|
5:30 PM | 227 | Blockade of Soluble Epoxide Hydrolase Attenuates Post-Ischemic Neuronal Hyperexcitation and Confers Resilience Against Stroke with TrkB Activation |
Li-Hsin Chang Disclosure: Dr. Chang has nothing to disclose.
|
5:30 PM | 228 | Characterizing the Neuroinflammatory Response of Focal Ischemic Stroke in the Rat Insular Cortex |
Victoria Thorburn Disclosure: Dr. Thorburn has nothing to disclose.
|
5:30 PM | 229 | Association of plasma D-dimer and B-type natriuretic peptide levels with stroke mechanism, severity, and outcome |
Hyun-Wook Nah Disclosure: Dr. Nah has nothing to disclose.
|
5:30 PM | 230 | Role Of Blood Biomarkers In Differentiating Ischemic Stroke and Intracerebral Hemorrhage |
Rohit Bhatia, MBBS,MD,DM Disclosure: Dr. Bhatia has nothing to disclose.
|
5:30 PM | 231 | Circulating inflammatory biomarkers are related to cerebrovascular disease in a non-demented elderly population |
Yian Gu, PhD,DrPH Disclosure: Dr. Schupf has nothing to disclose.
|
5:30 PM | 232 | Diapedetic Potential of Monocytes in Complexes with Platelets Correlates with Clinical Outcome after Stroke |
Maria Lukasik Disclosure: Dr. Lukasik has nothing to disclose.
|
5:30 PM | 233 | Multiple Biomarkers for the Prediction of Stroke Outcomes: Findings from a Cohort of 792 Patients with Ischemic Stroke in a University Teaching Hospital |
Zuolu Liu Disclosure: Dr. Liu has nothing to disclose.
|
5:30 PM | 234 | Role Of Blood Biomarkers In Predicting Outcomes After Acute Stroke |
Divya M Radhakrishnan Disclosure: Dr. MR has nothing to disclose.
|
5:30 PM | 235 | Marked Leukocytosis on Presentation with Acute Ischemic Stroke -- What Does it Mean? |
Matthew Broderick, MD Disclosure: Dr. Broderick has nothing to disclose.
|
5:30 PM | 236 | Admission white blood cell count is associated with stroke severity and outcome independent of acute infarct size |
Anne-Katrin Giese Disclosure: Dr. Giese has nothing to disclose.
|
5:30 PM | 237 | Can S100b, IL 6 And BNP Predict Functional Neurological Outcome In Intracerebral Hemorrhage? |
Mohammed El-Sherif, MD Disclosure: Dr. El-Sherif has nothing to disclose.
|
5:30 PM | 238 | Role of Copeptin as a Biomarker for Predicting Outcome after Spontaneous Intracerebral Hemorrhage: A Prospective Cohort Study |
Shubham Misra Disclosure: Dr. Misra has nothing to disclose.
|
5:30 PM | 239 | Role of Blood Based Biomarkers for Predicting Outcome after Spontaneous Intracerebral Hemorrhage: Findings from a Multi-Centric Prospective Cohort Study |
Kameshwar Prasad, MD Disclosure: Dr. Prasad has nothing to disclose.
|
5:30 PM | 240 | A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for Ischemic Stroke |
I-Chen Yu Disclosure: Dr. Yu has nothing to disclose.
|
Cerebrovascular Genetics | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 241 | Molecular Genetic Features Of Polymorphism Of The Gene Col4a1 Rs605143 G / A In The Development Of Pathological Deformations Of Cerebral Vessels In Patients With Migraine |
Gulnora Rahmatullaeva Disclosure: Dr. Rahmatullaeva has nothing to disclose.
|
5:30 PM | 242 | The Cerebral Straight and Narrow: A Case Illustration of Moyamoya Syndrome in the Setting of the ACTA-2 Gene Mutation |
Malcolm McDonald Disclosure: Dr. McDonald has nothing to disclose.
|
5:30 PM | 243 | Rare Presentation of Malignant Myxomatous Aneurysms with PRKAR1A gene mutation |
Usman Shehzad, MD Disclosure: Dr. Shehzad has nothing to disclose.
|
5:30 PM | 244 | Molecular - Genetic Features Of The Gene Of Vasculoendothelial Growth Factor (C634G VEGFA) In The Deformations Of Cerebral Vessels |
Gulnora Rahmatullaeva Disclosure: Dr. Rahmatullaeva has nothing to disclose.
|
5:30 PM | 245 | PAI-1 polymorphism and stroke in pregnancy |
Mary Hollist, DO, MD Disclosure: Dr. Hollist has nothing to disclose.
|
5:30 PM | 246 | Ring-enhancing lesions, stroke and vascular retinopathy associated with a novel TREX1 mutation |
Marcus Cimino, MD Disclosure: Dr. Cimino has nothing to disclose.
|
5:30 PM | 247 | Systemic Response to Rupture of Intracranial Aneurysms Analyzed with Whole-transcriptome Sequencing |
Joanna Pera, MD Disclosure: Dr. Pera has nothing to disclose.
|
5:30 PM | 248 | Association of Transforming growth Factor-?1 gene C509T, G800A and T869C Polymorphisms with Intracerebral Hemorrhage in North Indian Population: A Case-Control Study |
Shubham Misra Disclosure: Dr. Misra has nothing to disclose.
|
5:30 PM | 249 | Role Of Pharmacogenetics and Pharmacodynamics On The Antiplatelet Effect Of Clopidogrel In North Indian Ischemic Stroke Patients |
Dheeraj Khurana, MD Disclosure: Dr. Khurana has nothing to disclose.
|
5:30 PM | 250 | Association between Tumor necrosis factor-alpha (-308G/A, +488G/A, -857C/T and -1031 T/C) gene polymorphisms and risk of ischemic stroke in north Indian population: A case-control study |
Pumanshi Talwar Disclosure: Dr. Talwar has nothing to disclose.
|
Pre-Hospital, Telestroke and ED-Based Stroke Care II | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 251 | Safety and Feasibility of Telestroke in the Prehospital Emergency Medical Services Setting - The REACHOUT Project |
Muhammad Adeel Saleemi Disclosure: Dr. Saleemi has nothing to disclose.
|
5:30 PM | 252 | Pre-arrival RACE Score-Based Hospital Bypass Protocol Improves Treatment Time Efficiencies |
Shazli Khan Disclosure: Dr. Khan has nothing to disclose.
|
5:30 PM | 253 | Correlation between evaluation and documentation of neurologic deficit by EMS and ED of patients with acute ischemic stroke |
Haitham Hussein, MD Disclosure: Dr. Hussein has nothing to disclose.
|
5:30 PM | 254 | A Prospective Validation of Stroke Network Of Wisconsin (SNOW) Scale |
Kessarin Panichpisal Disclosure: Dr. Panichpisal has nothing to disclose.
|
5:30 PM | 255 | Safety of intravenous thrombolysis in telestroke and impact of an acute stroke training curriculum |
Tarun Girotra, MD Disclosure: Dr. Girotra has nothing to disclose.
|
5:30 PM | 256 | NA |
NA NA Disclosure:
|
5:30 PM | 257 | NA |
NA NA Disclosure:
|
5:30 PM | 258 | NA |
NA NA Disclosure:
|
Clinical Epilepsy II | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 259 | Baroreflex Sensitivity in Patients with Intractable Generalized Tonic Clonic Seizures versus Partial Seizures |
Behnaz Esmaeili, MD Disclosure: Dr. Esmaeili has nothing to disclose.
|
5:30 PM | 260 | Evaluation of Dual Pathology Among Drug Resistant Epileptic Patients With Hippocampal Sclerosis |
Peyman Gookizadeh Disclosure: Dr. Gookizadeh has nothing to disclose.
|
5:30 PM | 261 | A New Database Platform for Clinical and Genetic Investigation of Epilepsies and the New ILAE Classification |
David Discua Disclosure: Dr. Discua has nothing to disclose.
|
5:30 PM | 262 | Initial Presentations and Surgical Outcomes of Pediatric Patients with Neurovascular Lesions |
Janani Kassiri, MD, PhD Disclosure: Dr. Kassiri has nothing to disclose.
|
5:30 PM | 263 | Comparing the Clinical Profile and Seizure Control between Focal and Generalized Seizures in Adult Nigerian Patients with Epilepsy. |
Chindo Mallum, MD Disclosure: Dr. Mallum has nothing to disclose.
|
5:30 PM | 264 | A Fatal Case of Mistaken Identity: Brugada Syndrome Masquerading as Seizure Disorder |
Claribel Wee, MD Disclosure: Dr. Wee has nothing to disclose.
|
5:30 PM | 265 | Impact of Seizures in Temporal Lobe Epilepsy on Cognitive Functions and Imaging Features |
Gyujoon Hwang Disclosure: Dr. Hwang has nothing to disclose.
|
5:30 PM | 266 | Clinical Significance of Bilateral Failures on Wada Memory Testing |
Iffat Ara Suchita, MD Disclosure: Dr. Suchita has nothing to disclose.
|
5:30 PM | 267 | Seizure-induced Behavioral and Autonomic Arousal Localizes to the Anterior Cingulate Gyrus: Network Dynamics and Underlying Mechanism |
Harshad Ladha, MD Disclosure: Dr. Ladha has nothing to disclose.
|
5:30 PM | 268 | Does A Drug Refractory Epilepsy (DRE) diagnosis impact time to seizures in the Epilepsy Monitoring Unit (EMU) |
Brian Toh Disclosure: Dr. Toh has nothing to disclose.
|
5:30 PM | 269 | The Role Of Immunoreactivity Of Neurotropic Autoantibodies And Neuromediators In The Pathogenesis Of Symptomatic And Idiopathic Epilepsy |
Marufjon Salokhiddinov Disclosure: Dr. Salokhiddinov has nothing to disclose.
|
5:30 PM | 270 | Epilepsy as a Dynamic Disease: Modeling Seizure Burden Based On Transitions Between Seizure Risk States |
Sharon Chiang Disclosure: Dr. Chiang has nothing to disclose.
|
5:30 PM | 271 | Effect of Anesthesia on Electrocorticography for localization of Epileptic Focus: Literature Review and Future Directions |
Ayse Bayram Disclosure: Dr. Bayram has nothing to disclose.
|
5:30 PM | 272 | Can We Predict the prognosis in patients with Acute Symptomatic Seizure? A Prognostic model: A Retrospective study from a developing nation |
GOPAL KRISHNA DASH Disclosure: Dr. Dash has nothing to disclose.
|
Epilepsy: Basic Science and Genetics | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 273 | Characterization of a Novel Knock-in Mouse Model of KCNT1 Epileptic Encephalopathy |
Lisseth Burbano Disclosure: Dr. Burbano has nothing to disclose.
|
5:30 PM | 274 | NLRP1 Inflammasome is Activated in Patients with Medial Temporal Lobe Epilepsy and Contributes to Neuronal Pyroptosis in Amygdala Kindling- induced Rat Model |
Chenchen Tan Disclosure: Dr. Tan has nothing to disclose.
|
5:30 PM | 275 | Autophagy in Juvenile Myoclonic Epilepsy (JME) |
Miyabi Tanaka Disclosure: Dr. Tanaka has nothing to disclose.
|
5:30 PM | 276 | NADPH oxidase inhibitor attenuated increased seizure susceptibility after systemic inflammation |
Wan-Yu Huang Disclosure: Dr. Huang has nothing to disclose.
|
5:30 PM | 277 | A role of GPR55 in the antiepileptic properties of cannabidiol (CBD) |
Benjamin J. Whalley Disclosure: Dr. Whalley is employed by GW Pharmaceuticals. Dr. Whalley holds stock and/or stock options in GW Pharmaceuticals, which sponsored research in which Dr. Whalley was involved as an investigator.
|
5:30 PM | 278 | Variation in Cortical Impact Augments Epileptogenesis in Rat Model of Traumatic Brain Injury. |
SHAMMY CHANDEL Disclosure: Dr. Chandel has nothing to disclose.
|
5:30 PM | 279 | Protective effects of protocatechuic acid against seizure-induced neuronal death in the pilocarpine-induced status epilepticus rat model |
Dong Jin Shin, MD Disclosure: Dr. Shin has nothing to disclose.
|
5:30 PM | 280 | Association Between Occurrence of Hippocampal Spindles and Hippocampal Interictal Spiking. |
Kseniia K. Kriukova Disclosure: Dr. Kriukova has nothing to disclose.
|
5:30 PM | 281 | Majority of Epilepsy Mutations are in Genes with Therapeutic Associations |
Elaine Weltmer Disclosure: Dr. Weltmer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ambry Genetics.
|
5:30 PM | 282 | Genotype and Phenotype Correlation in Patients with Comorbid Epilepsy and Intellectual Disability |
Mohamed Taha, MD Disclosure: Dr. Taha has nothing to disclose.
|
5:30 PM | 283 | Screening of PI3K-AKT-mTOR pathway genes in focal cortical dysplasias in a clinical setting |
Andrea Accogli Disclosure: Dr. Accogli has nothing to disclose.
|
5:30 PM | 286 | Prevalence and Impact of Consanguinity in Patients with Mesial Temporal Sclerosis in Saudi Population |
Khalid Alqadi, MD Disclosure: Dr. Alqadi has nothing to disclose.
|
5:30 PM | 287 | Refractory Status Epilepticus and Chronic Kidney Disease in a Large Pedigree Due to a Variant in the Mitochondrial Encoded tRNA Phenylalanine (MT-TF) Gene |
James H. Ellis, BS Disclosure: Dr. Ellis has nothing to disclose.
|
5:30 PM | 288 | Analysis of 234 Epilepsy Genes for Sequence and Copy Number Variants Using Next Generation Sequencing |
Zhenyuan Wang Disclosure: Dr. Wang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Quest Diagnostics. Dr. Wang has received research support from Quest Diagnostics.
|
5:30 PM | 289 | Genetic Testing has taken out Guesswork: Cases of Familial and Non-familial Benign Infantile Epilepsy Associated with PRRT2 gene mutations. |
Yoshimi Hisamoto, MD Disclosure: Dr. Hisamoto has nothing to disclose.
|
5:30 PM | 290 | NA |
NA NA Disclosure:
|
5:30 PM | 291 | NA |
NA NA Disclosure:
|
5:30 PM | 292 | NA |
NA NA Disclosure:
|
5:30 PM | 293 | NA |
NA NA Disclosure:
|
5:30 PM | 294 | NA |
NA NA Disclosure:
|
Child Neurology and Developmental Neurology: Epilepsy | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 295 | EEG Patterns in Routine Polysomnography in Childhood and Risk of Epilepsy |
Robert Stowe, MD Disclosure: Dr. Stowe has nothing to disclose.
|
5:30 PM | 296 | New Onset Refractory Status Epilepticus in Pediatric Population: A Single Tertiary Center Experience |
Khalil Husari, MD Disclosure: Dr. Husari has nothing to disclose.
|
5:30 PM | 297 | Cognitive, Linguistic and Behavioral Characteristics of Children with Comorbid Autism Spectrum Disorder and Epilepsy |
Louisa Kalsner, MD Disclosure: Dr. Kalsner has nothing to disclose.
|
5:30 PM | 298 | Evaluation of new onset seizures presenting to the Pediatric Emergency Department(ED). A quality improvement study based on the AAN, CNS and AES practice parameters (2010). |
Nitish Chourasia, MD Disclosure: Dr. Chourasia has nothing to disclose.
|
5:30 PM | 299 | Cognitive Outcomes In Children With Infantile Spasms: Successful Treatment Response Is Beneficial Regardless Of Etiology |
Nonita Mittal, MBBS Disclosure: Dr. Mittal has nothing to disclose.
|
5:30 PM | 300 | The clinical and electroencephalographic spectrum of ESES (Encephalopathy with status epilepticus in sleep) in Indian children |
Priyanka Madaan Disclosure: Dr. Madaan has nothing to disclose.
|
5:30 PM | 301 | Long-Term Prognostic Patterns In Pediatric Epilepsy: A Review Of Literature. |
Kushal Naik Disclosure: Dr. Naik has nothing to disclose.
|
5:30 PM | 302 | Rectal Administration of Vigabatrin Achieves Higher Plasma Concentration than Oral Administration. |
Mohammad Hamed Disclosure: Dr. Hamed has nothing to disclose.
|
5:30 PM | 303 | Utilizing Quality Improvement Strategies to Increase Continuous EEG Monitoring in Critically Ill Pediatric Patients with Persistent Encephalopathy Following Status Epilepticus |
Asri Yuliati Disclosure: Dr. Yuliati has nothing to disclose.
|
5:30 PM | 304 | Expanding the clinical spectrum of the rare epilepsy syndrome of Benign Infantile Focal Epilepsy with Midline Spikes (BIMSE) |
Reema Butt Disclosure: Dr. Butt has nothing to disclose.
|
5:30 PM | 305 | Drug-Resistant Epilepsy and Neurodevelopmental Disabilities in Randomized Controlled Trials of Therapeutic Devices |
Lydia Bernhardt Disclosure: Dr. Bernhardt has nothing to disclose.
|
Child Neurology and Developmental Neurology: Infectious, Inflammatory, and Autoimmune Disorders | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 306 | The Spectrum of Myelopathies in Children: Beyond Idiopathic Transverse Myelitis |
Laura Munoz-Arcos, MD Disclosure: Dr. Munoz-Arcos has nothing to disclose.
|
5:30 PM | 307 | Cerebrospinal fluid (CSF) Neurofilament and CXCL-13 Levels in Children with Demyelinating Disease |
Maria Galardi Disclosure: Dr. Galardi has nothing to disclose.
|
5:30 PM | 308 | Pediatric and Adult MS: A Longitudinal Multimodal MRI Study to Explore the Substrates of the Different Clinical Courses |
Ermelinda De Meo Disclosure: Dr. De Meo has nothing to disclose.
|
5:30 PM | 309 | Chitinase 3-like 1 and Neurofilament Light Chain Predict Pediatric Demyelination |
Magnus Spangsberg Boesen Disclosure: Dr. Spangsberg Boesen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva and Novartis. Dr. Spangsberg Boesen has received research support from Teva, Novartis, and Genzyme.
|
5:30 PM | 310 | CT Scan Findings in Microcephaly Cases During 2015-2016 Zika Outbreak: A Cohort Study |
Tabata De Alcantara Disclosure: Dr. De Alcantara has nothing to disclose.
|
5:30 PM | 311 | Use of Induction Immunotherapy Plus Rituximab for the Treatment of Pediatric Opsoclonus-Myoclonus Syndrome |
Colin Wilbur, MD Disclosure: Dr. Wilbur has nothing to disclose.
|
5:30 PM | 312 | To determine the prevalence of neurologic syndromes, intellectual disability, abnormal behavior and sleep related problems in HIV infected children |
Rajni Farmania Disclosure: Dr. Farmania has nothing to disclose.
|
5:30 PM | 313 | Autoimmune encephalitis in children: Clinical profile and outcome from a single tertiary care centre in India |
Sheffali Gulati Disclosure: Dr. Gulati has nothing to disclose.
|
5:30 PM | 314 | Radiological Findings and Neurological Disorders in Microcephaly Cases Related to Zika Virus: A Cohort Study |
Tabata De Alcantara Disclosure: Dr. De Alcantara has nothing to disclose.
|
5:30 PM | 315 | Gait variability is related to attention and information processing speed in adolescents with multiple sclerosis |
Shay Menascu Disclosure: Dr. Menascu has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi-Genzyme and Merck/EMD Serono.
|
5:30 PM | 316 | A Case of Cognitive and Behavioral Decline leading to Onset of Pediatric Onset Multiple Sclerosis |
Janet Elgallab, MD Disclosure: Dr. Elgallab has nothing to disclose.
|
5:30 PM | 317 | A Case Series of Acute Flaccid Myelitis in Pediatric Patients |
Lydia Marcus, MD Disclosure: Dr. Marcus has nothing to disclose.
|
5:30 PM | 318 | Imaging of the Mechanisms of Thalamic Damage in Pediatric Multiple Sclerosis |
Ermelinda De Meo Disclosure: Dr. De Meo has nothing to disclose.
|
5:30 PM | 319 | Miller Fisher Syndrome in a Case of Identical Twins |
Tayyba Anwar, MD Disclosure: Dr. Anwar has nothing to disclose.
|
5:30 PM | 320 | Pediatric Acute Flaccid Myelitis: A Case Series |
Alison Christy, MD, PhD Disclosure: Dr. Christy has nothing to disclose.
|
5:30 PM | 321 | Chiari malformations associated with transverse myelitis: are these myelopathies truly inflammatory? |
Eliza Gordon-Lipkin, MD Disclosure: Dr. Gordon-Lipkin has nothing to disclose.
|
Child Neurology and Developmental Neurology: Neuromuscular Disease | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 322 | Ambulatory function and fatigue in nusinersen-treated children with spinal muscular atrophy. |
Jacqueline Montes, PT, EdD, NCS Disclosure: Dr. Montes has received personal compensation for activities compensation for consulting, serving on a scientific advisory board, speaking, or other activities with ISIS Pharmaceuticals, Inc.
|
5:30 PM | 323 | Safety profile of abobotulinumtoxinA (Dysport®) for lower limb spasticity: Pooled analysis of controlled clinical trials |
Ann Tilton, MD, FAAN Disclosure: Dr. Tilton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen Pharma. Dr. Tilton has received research support from Ipsen Pharma.
|
5:30 PM | 324 | Safety and Efficacy of Nusinersen in Infants/Children with Spinal Muscular Atrophy (SMA): Part 1 of the Phase 2 EMBRACE Study |
Perry B. Shieh, MD, PhD Disclosure: Dr. Shieh has nothing to disclose.
|
5:30 PM | 325 | Meta-Analysis of Deflazacort vs Prednisone/Prednisolone in Patients with Duchenne Muscular Dystrophy |
Basil Darras, MD Disclosure: Dr. Darras has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, Biogen, Cytokinetics, Marathon Pharmaceuticals, PTC Therapeutics, Roche, Sarepta, Bristol-Myers Squibb, and Ionis Pharmaceuticals, Inc. Dr. Darras has received research support from Ionis Pharmaceuticals, Inc. for the ENDEAR, CHERISH, CS2/CS12 studies, from Biogen for CS11 , as well as from Cytokinetics, PTC Therapeutics, Fibrogen, and Summit.
|
5:30 PM | 326 | Pediatric Myasthenia Gravis After Vaccination in the United States. A Report from the CDC/FDA Vaccine Adverse Event Reporting System. (1990-2017) |
Rajanigandhi Hanumanthu, MD Disclosure: Dr. Hanumanthu has nothing to disclose.
|
5:30 PM | 327 | Evaluation of Childhood Weakness: Utilization of a Web-Based Educational Tool childmuscleweakness.org |
Ann Martin Disclosure: Dr. Martin has nothing to disclose.
|
5:30 PM | 328 | Predicting Ambulatory Aid Needs with Disease Progression in Charcot-Marie-Tooth Disease |
Sindhu Ramchandren, MD Disclosure: Dr. Ramchandren has nothing to disclose.
|
5:30 PM | 329 | Design of a Phase 3 Trial to Evaluate the Long-Term Efficacy and Safety of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy |
Panayiota Trifillis Disclosure: Dr. Trifillis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics, Inc.
|
5:30 PM | 330 | Assessment of Practice Patterns and Knowledge of Pathophysiology for Spinal Muscular Atrophy Among Neurologists |
John Maeglin Disclosure: Dr. Maeglin has nothing to disclose.
|
5:30 PM | 331 | Slope Analysis of 6-Minute Walk Dstance as an Alternative Method to Determine Treatment Effect in Trials in Duchenne Muscular dystrophy |
Panayiota Trifillis Disclosure: Dr. Trifillis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics, Inc.
|
5:30 PM | 332 | Tolerability of Eteplirsen for Duchenne Muscular Dystrophy in the Youngest Reported Patient Treated With This Therapy |
Sonam Bhalla, MD Disclosure: Dr. Bhalla has nothing to disclose.
|
5:30 PM | 333 | Cervical Puncture to Deliver Nusinersen in Patients with Spinal Muscular Atrophy and no Lumbar Access |
Aravindhan Veerapandiyan, MD Disclosure: Dr. Veerapandiyan has nothing to disclose.
|
5:30 PM | 334 | A unique presentation of rapidly fluctuating symptoms in a child diagnosed with Congenital Myasthenic Syndrome due to RAPSN mutation. |
Ashutosh Kumar, MD Disclosure: Dr. Kumar has received research support from Marathon and Sarepta Therapeutics.
|
5:30 PM | 335 | Focal Myositis of the Iliopsoas in a Young Girl with Recurrent Symptoms: A Case Report |
Stephanie Manberg, DO Disclosure: Dr. Manberg has nothing to disclose.
|
5:30 PM | 336 | Unexpected Neuromuscular Diagnoses from Chromosomal Microarrays |
Rebecca Luke, DO Disclosure: Dr. Luke has nothing to disclose.
|
5:30 PM | 337 | NA |
NA NA Disclosure:
|
5:30 PM | 338 | NA |
NA NA Disclosure:
|
Epilepsy/Clinical Neurophysiology (EEG) ePoster Session | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 339 | Seizure Risk From Intraoperative Motor Evoked Potential Stimulation |
Viet Nguyen, MD Disclosure: Dr. Nguyen has nothing to disclose.
|
5:30 PM | 340 | Mesial Temporal Sclerosis (MTS) Undetected by MRI of the Brain |
Miad Albalawi, MD Disclosure: Dr. Albalawi has nothing to disclose.
|
5:30 PM | 341 | Long Term Effects of Vagal Nerve Stimulation on Seizure Control and Quality of Life |
Justin Abraham, MD Disclosure: Dr. Abraham has nothing to disclose.
|
5:30 PM | 342 | Unilateral deep brain stimulation masks undiagnosed epilepsy in a Parkinson's Disease patient: A Case Report |
Alexis Taylor Disclosure: Dr. Taylor has nothing to disclose.
|
5:30 PM | 343 | EEG Cap Placement for Expedited Identification of Non-Convulsive Status Epilepticus |
Jake McKay, MD Disclosure: Dr. McKay has nothing to disclose.
|
5:30 PM | 344 | Analyzing Phenotypes Using Artificial Intelligence Tools in Subgroups of Absence and Myoclonic Epilepsies |
Reyna M. Durón Disclosure: Dr. Duron has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbot.
|
MS Modifiable Risk Factors | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 345 | Hypertension and heart disease are independently associated with development of brain atrophy in multiple sclerosis patients. A 5-year longitudinal study |
Dejan Jakimovski Disclosure: Dr. Jakimovski has nothing to disclose.
|
5:30 PM | 346 | The Impact of Socioeconomic Status on Treatment Choice in Patients with Multiple Sclerosis. |
Saul Reyes Disclosure: Dr. Reyes has nothing to disclose.
|
5:30 PM | 347 | Vitamin D and physical activity in multiple sclerosis |
Florian Deisenhammer, MD Disclosure: Dr. Deisenhammer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Celgene, Genzyme, Merck, Novartis, Roche, and TEVA. Dr. Deisenhammer has received research support from by Biogen and Genzyme-Sanofi..
|
5:30 PM | 348 | Depression Severity Among Multiple Sclerosis Patients In Saudi Arabia-Cross Sectional Study |
Adel Ali Alhazzani Disclosure: Dr. Alhazzani has nothing to disclose.
|
5:30 PM | 349 | Vitamin B12 and its impact on Multiple Sclerosis Type and Severity |
Shymaa Buhlaiqah Disclosure: Dr. Hussain has nothing to disclose.
|
5:30 PM | 350 | Cesarean delivery and artificial lactation are associated with an earlier age of disease onset in multiple sclerosis |
Vittorio Martinelli Disclosure: Dr. Martinelli has nothing to disclose.
|
5:30 PM | 351 | Distinct Effects of Obesity and Vitamin D on Risk of Multiple Sclerosis: A Mendelian Randomization Study |
Adil Harroud, MD Disclosure: Dr. Harroud has nothing to disclose.
|
5:30 PM | 352 | Vitamin D Levels and Clinical and OCT measures in Progressive Multiple Sclerosis |
Justin Abbatemarco, MD Disclosure: Dr. Abbatemarco has nothing to disclose.
|
5:30 PM | 353 | Longer Sleep Duration is Linked to Preserved Cortical Gray Matter Volume in Early MS |
Michelle Fabian, MD Disclosure: Dr. Fabian has nothing to disclose.
|
5:30 PM | 354 | Risk Factors Associated with Multiple Sclerosis in Bogotá, Colombia. |
Jaime Toro, MD, FAAN Disclosure: Dr. Toro has received personal compensation in an editorial capacity for New England Journal of Medicine, Journal Watch Neurology and Multiple Sclerosis and Related Disorders.
|
5:30 PM | 355 | The Gut Microbiome in Relapsing Multiple Sclerosis Patients Compared to Controls. |
Raffaella Umeton, MD Disclosure: Dr. Umeton has nothing to disclose.
|
5:30 PM | 356 | Fecal Microbial Transplantation in Multiple Sclerosis: trial design. |
Ana Cristina Wing Disclosure: Dr. Dos Santos has nothing to disclose.
|
5:30 PM | 357 | Gut microbiota and metagenomic diversity in Clinical Isolated Syndrome |
Simona Rolla Disclosure: Dr. Rolla has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi-Genzyme.
|
5:30 PM | 358 | A Paleolithic Diet-Based Intervention Decreases Multiple Sclerosis Fatigue via Lipid Profile Changes |
Murali Ramanathan, PhD Disclosure: Dr. Ramanathan has nothing to disclose.
|
5:30 PM | 359 | Stress-induced Brain Activity, Brain Atrophy, and Clinical Disability in Multiple Sclerosis |
Lil Meyer-Arndt Disclosure: Dr. Meyer-Arndt has nothing to disclose.
|
5:30 PM | 360 | Case Series of Four High School Football Players with Multiple Sclerosis |
Cynthia Wang, MD Disclosure: Dr. Wang has nothing to disclose.
|
5:30 PM | 361 | Nutrition in the First Year Following the Diagnosis of Multiple Sclerosis |
Yujie Wang, MD Disclosure: Dr. Wang has nothing to disclose.
|
MS Diagnosis, Mimickers, and Phenotypes | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 362 | Sarcoidosis Presenting as Intramedullary Spinal Cord Lesions |
Prateek Thatikunta Disclosure: Dr. Thatikunta has nothing to disclose.
|
5:30 PM | 363 | When It's Not Multiple Sclerosis: Progressive White Matter Lesions with Inflammation |
Julia Bucklan, DO Disclosure: Dr. Bucklan has nothing to disclose.
|
5:30 PM | 364 | Comorbidity in ultiple Sclerosis is associated with Diagnostic Delays and Increased Mortality |
Anja Thormann Disclosure: Dr. Thormann has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adelphi Communications Ltd..
|
5:30 PM | 365 | Population-Based Prospective Cohort of RRMS Patients Who Declined or Delayed Disease-Modifying Therapy |
Abdulaziz Al Sultan Disclosure: Dr. Al Sultan has nothing to disclose.
|
5:30 PM | 366 | Assessment of Relative Importance of Disease Modifying Treatment (DMT) Attributes in Multiple Sclerosis (MS) Patients |
Tobias Sejbaek Disclosure: Dr. Sejbaek has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Merck, Novartis, and Teva.
|
5:30 PM | 367 | Late Onset Fabry Disease: A Mimicker of CNS Demyelinating Disease |
Subhendu Rath, MBBS Disclosure: Dr. Rath has nothing to disclose.
|
5:30 PM | 368 | The phenotype of Argentinean Multiple Sclerosis patients is similar to Multiple Sclerosis patients from other regions and has remained stable over the past decade. |
Mariano Marrodan Disclosure: Dr. Marrodan has nothing to disclose.
|
5:30 PM | 369 | Impact of Gender on 30-day Readmission After Primary Admissions for Multiple Sclerosis: A Nationwide Readmission Database Analysis |
Smit Patel Disclosure: Dr. Patel has nothing to disclose.
|
5:30 PM | 370 | Residual disability of acute severe multiple sclerosis relapses |
Anat Achiron, MD, PhD, FAAN Disclosure: Dr. Achiron has nothing to disclose.
|
5:30 PM | 371 | Clinical and Immunologic Characterization of MRI-Defined Phenotypes in Multiple Sclerosis: a Longitudinal Study |
Christopher Hemond, MD Disclosure: Dr. Hemond has nothing to disclose.
|
5:30 PM | 372 | Retinal Vasculopathy with Cerebral Leukoencephalopathy (RVCL): A Rare Familial Mimic of Tumefactive Multiple Sclerosis (MS) |
Asaff Harel, MD Disclosure: Dr. Harel has nothing to disclose.
|
5:30 PM | 373 | An Extremely Aggressive case of Marburg's Disease |
Jose Avila-Ornelas, MD Disclosure: Dr. Avila-Ornelas has nothing to disclose
|
5:30 PM | 374 | Spectrum of Peripheral Facial Involvement in Central Demyelinating Diseases |
Elias Samaha, MD Disclosure: Dr. Samaha has nothing to disclose.
|
MS Epidemiology and Genetics | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 375 | Impact of age at relapse on recovery: An EDSS-recovery model for clinical trials |
Burcu Zeydan, MD Disclosure: Dr. Zeydan has nothing to disclose.
|
5:30 PM | 376 | Predictors of Vocational Status Among Persons with Multiple Sclerosis |
Sarah Morrow, MD, MSC,FRCPC Disclosure: Dr. Morrow has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, EMD Serono, Genzyme, Novartis, and Roche. Dr. Morrow has received research support from Novartis and Roche.
|
5:30 PM | 377 | Relevance of Age and Cerebrospinal Fluid Measures in Multiple Sclerosis associated with seizures |
Shitiz Sriwastava, MBBS Disclosure: Dr. Sriwastava has nothing to disclose.
|
5:30 PM | 378 | Bone Microarchitecture and Bone Mineral Density in Multiple Sclerosis |
Anna Olsson Disclosure: Dr. Olsson has received research support from has received support for congress participation from Teva and Merck.
|
5:30 PM | 379 | Impact of multiple comorbidities on EDSS at presentation in patients with multiple sclerosis: A cross-sectional study. |
Faisal Alsallom, MD Disclosure: Dr. Alsallom has nothing to disclose.
|
5:30 PM | 380 | Estimated prevalence of secondary progressive multiple sclerosis in the USA and Europe: results from a systematic literature search |
Vivek Khurana Disclosure: Dr. Khurana has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Healthcare Private Limited.
|
5:30 PM | 381 | Erdheim-Chester Disease in the Brainstem Mimicking Tumefactive Demyelination. |
Maria del Pilar Guillermo Prieto Eibl Disclosure: Dr. Prieto Eibl has nothing to disclose.
|
5:30 PM | 382 | Differential Expression of Alternative Splicing Variants in Individuals with Relapsing-Remitting Multiple Sclerosis |
Michael Hecker, PhD Disclosure: Dr. Hecker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer HealthCare, Biogen, Novartis and Teva.
|
5:30 PM | 383 | Development of Multiple Sclerosis relapse flare after Vaccination, A CDC/FDA Vaccine Adverse Event Reporting System (VAERS) Study, [1987-2017]. |
Moamina Fakhera Eddin Disclosure: Dr. Fakhera Eddin has nothing to disclose.
|
5:30 PM | 384 | EMPLOYMENT SITUATION IN BRAZILIAN PATIENTS DIAGNOSED WITH MULTIPLE SCLEROSIS |
Denis Bichuetti, MD Disclosure: Dr. Bichuetti has received personal compensation for speaking/consulting from Bayer Health Care, Biogen Idec, Merck Serono, Genzyme-Sanofi, TEVA and Roche, and had travel expenses to scientific meetings sponsored by Bayer Health Care, Merck Serono, TEVA and Roche.
|
5:30 PM | 385 | Impact of Age on 30-day Readmission After Primary Admission for Multiple Sclerosis: A Nationwide Readmission Databse Analysis |
Smit Patel Disclosure: Dr. Patel has nothing to disclose.
|
5:30 PM | 386 | The Prevalence and Special Characteristic of Multiple Sclerosis that Begins in Older Adults |
Estefanía García Molina Disclosure: Dr. Valero López has nothing to disclose.
|
5:30 PM | 387 | Does Co-morbidity with Familial Mediterranean Fever change the course of Multiple Sclerosis? |
Aksel Siva, MD Disclosure: Dr. Siva has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Novartis, Teva, Genzyme, Bayer, and Roche.
|
5:30 PM | 388 | Protective role of Multiple Sclerosis in Stroke; Analysis of a large national data base |
Maryam Zulfiqar Disclosure: Dr. Zulfiqar has nothing to disclose.
|
5:30 PM | 389 | A Whole-Exome Sequencing Study In Multiple Sclerosis Multiplex Families |
Elisabetta Mascia Disclosure: Dr. Mascia has nothing to disclose.
|
5:30 PM | 390 | The Saudi Arabian National Multiple Sclerosis Registry (NMSR): Initial Results Saudi MS Registry Study Group* |
M. Al-Jumah, MD, MBBS Disclosure: Dr. Al-Jumah has nothing to disclose.
|
5:30 PM | 391 | Demyelination and Neurodegeneration along the Visual Pathway are more prominent in Secondary Progressive than Primary Progressive Multiple Sclerosis. |
Simone Guerrieri Disclosure: Dr. Guerrieri has nothing to disclose.
|
5:30 PM | 392 | Regional thalamic volumes preferentially correlate with extra-thalamic white matter injury and clinical disability in multiple sclerosis subtypes |
Kedar Mahajan, MD, PhD Disclosure: Dr. Mahajan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme.
|
5:30 PM | 393 | Predictors of Conversion to Secondary Progressive Multiple Sclerosis in Patients With Relapsing-Remitting Multiple Sclerosis |
Davorka Tomic Disclosure: Dr. Tomic is an employee of Novartis Pharma AG.
|
5:30 PM | 394 | Predicting Physical and Mental Disability in Patients with Multiple Sclerosis: a Longitudinal Analysis of Electronic Health Records. |
Farren Briggs Disclosure: Dr. Briggs has nothing to disclose.
|
5:30 PM | 395 | New versus old: Implications of diagnostic criteria for Relapsing Remitting Multiple Sclerosis |
Nuala McNicholas, MBBS Disclosure: Dr. McNicholas has nothing to disclose.
|
5:30 PM | 396 | Familial Multiple Sclerosis: An Epidemiological Study in Pontevedra, Spain. |
Ana Rodriguez Regal Disclosure: Dr. Rodriguez Regal has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme, Biogen and TEVA.
|
5:30 PM | 397 | Increased Risk of Ischemic Stroke Associated with Untreated Multiple Sclerosis: A Nationwide Case-Control Population-Based Study. |
Asad Ikram, MD, MBBS Disclosure: Dr. Ikram has nothing to disclose.
|
5:30 PM | 398 | The North American Registry for Care and Research in Multiple Sclerosis |
Anne H. Cross, MD Disclosure: Dr. Cross has received personal compensation for activities with AbbVie, BAYER, Biogen, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Novartis, and Teva. Dr. Cross has received research support for Genentech/ Roche.
|
5:30 PM | 399 | Long-term disability outcomes in relapsing-remitting multiple sclerosis: A 10-year follow-up study |
Jelena Drulovic Disclosure: Dr. Drulovic has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with advisory boards: Bayer Schering Pharma, merck Serono, Teva, Genzyme, a Sanofi Company, Merck Serono, teva, Bayer Schering, genzyme, a Sanofi Company, Medis, and Roche. Dr. Drulovic has received research support from research grant support: Ministry of Education and Science, and The Republic of Serbia (project no. 175031).
|
5:30 PM | 400 | Patient Perspectives on Discontinuing Disease Modifying Therapies in the NARCOMS Registry |
Marisa McGinley, DO Disclosure: Dr. McGinley has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme.
|
MS Animal Models | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 401 | Astrocyte Transciptomics in EAE Lead to Cholesterol Homeostasis as a New Treatment Target |
Noriko Itoh Disclosure: Dr. Itoh has nothing to disclose.
|
5:30 PM | 402 | Longitudinal Diffusion Tensor Imaging in Theiler's Murine Encephalomyelitis Virus Driven Mouse Model of MS Reveals White Matter Change |
Ely Cuberos Disclosure: Dr. Cuberos has nothing to disclose.
|
5:30 PM | 403 | Interaction of Normal and Antineuronal IgGs with Neurons in Rat Brain Slice Cultures: Comparison of IgG Uptake, Clearance, Intraneuronal Binding to Target Antigens, and Production of Neuronal Death |
John Greenlee, MD, FAAN Disclosure: Dr. Greenlee has received personal compensation in an editorial capacity for Associate Editor for Medlink.
|
5:30 PM | 404 | Estrogen Receptor ? Ligand Acts on Two Pathways Within the CNS to Mediate Neuroprotection in the MS Model |
Roy Kim Disclosure: Dr. Kim has nothing to disclose.
|
5:30 PM | 405 | Cellular Senescence Correlates with Demyelination, Brain Atrophy and Motor Impairment in a Model of Multiple Sclerosis |
Maria Karamita Disclosure: Dr. Karamita has nothing to disclose.
|
5:30 PM | 406 | IL-11 antagonist suppresses Th17 cells-mediated neuroinflammation and demyelination in a mouse model of relapsing-remitting multiple sclerosis |
Xin Zhang Disclosure: Dr. Zhang has nothing to disclose.
|
5:30 PM | 407 | IL-11-stimulated Encephalitogenic CD4+ Cells Induce Aggressive RREAE, Mediated via Th17, CD8+, CD19+ Cells and Neutrophils' Migration to CNS in Passive Transfer RREAE |
Nazanin Kiapour Disclosure: Dr. Kiapour has nothing to disclose.
|
5:30 PM | 408 | Teriflunomide (Aubagio®) decreases microglial density in Theiler's Murine Encephalomyelitis Virus model of demyelination: Histological approach in combination with neuroimaging |
Suyog Pol, PhD Disclosure: Dr. Pol has nothing to disclose.
|
5:30 PM | 409 | BDNF is necessary for neuronal activity-regulated oligodendrogenesis |
Anna Geraghty Disclosure: Dr. Geraghty has nothing to disclose.
|
5:30 PM | 410 | Effect of Subcutaneous vs Intravenous Chronic Treatment with an Anti-CD20 Antibody on B-, T- and Myeloid Lymphocyte Subsets in Blood, Lymph Nodes and Spleen of C57BL/6 Mice |
Anna Schubart Disclosure: Dr. Schubart is and employee of Novartis.
|
5:30 PM | 411 | Complete Resolution of Clinical Signs and Synergism of the Combination Ponesimod-dimethyl Fumarate in Rat Models of Multiple Sclerosis |
Laetitia Pouzol Disclosure: Dr. Pouzol has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion Pharmaceuticals Ltd.
|
5:30 PM | 412 | Cerebrospinal Fluid Derived from Primary Progressive MS Delays Remyelination after Lysolecithin-induced Demyelination |
Nathan Kung Disclosure: Dr. Kung has nothing to disclose.
|
5:30 PM | 413 | Dietary Conjugated Linoleic Acid Supplementation Modulates CNS Autoimmunity |
Ann-Katrin Fleck Disclosure: Dr. Fleck has nothing to disclose.
|
5:30 PM | 414 | Passive transfer of human aquaporin-4 IgG autoantibodies causes complement-independent spinal cord immunopathologies in mice |
Koon Chan, MD, MBBS Disclosure: Dr. Chan has nothing to disclose.
|
MS and CNS Inflammatory Disease: Quality of Life, Symptoms, and Symptomatic Therapy II | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 415 | Neurocognitive Correlates of Impaired Perceptual Decision-Making in MS and their Link to Quality of Life |
Martin Weygandt, PhD Disclosure: Dr. Weygandt has nothing to disclose.
|
5:30 PM | 416 | Treatment satisfaction and illness perception in MS patients |
Jarrett Leech Disclosure: Dr. Leech has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Onnit Labs, LLC. Dr. Leech has received compensation for serving on the Board of Directors of Onnit Labs, LLC.
|
5:30 PM | 417 | Pain Network and Neuropsychological Profile in Multiple Sclerosis and Migraine Patients |
Claudio Gobbi, MD Disclosure: Dr. Gobbi has nothing to disclose.
|
5:30 PM | 418 | Neuroanatomical Correlates of Latent Variables Speed and Memory in Early Multiple Sclerosis |
Ilena George, MD Disclosure: Dr. George has nothing to disclose.
|
5:30 PM | 419 | Exploring Cannabis use by Patients with Multiple Sclerosis in a state where Cannabis is legal |
Laura J Weinkle Disclosure: Dr. Weinkle has nothing to disclose.
|
5:30 PM | 420 | Screening of cognitive impairment in patients with multiple sclerosis (MS): the BICAMS short version for patient-centered care in small neurological institutions |
Iris-Katharina Penner Disclosure: Dr. Penner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adamas Pharma, Bayer Pharma, Biogen GmbH, Desitin, Genzyme, Merck Serono, Novartis Pharma GmbH, Roche, and Teva. Dr. Penner has received research support from Teva.
|
5:30 PM | 421 | A new electronic and brief neuropsychological scale to detect cognitive impairment (CI) in patients with multiple sclerosis (MS): Validation study of the MS-COG-e scale |
José Meca Lallana Disclosure: Dr. Meca-Lallana has received consulting or speaking fees from Almirall, Biogen, Genzyme, Merck Serono, Novartis, Roche, and Teva.
|
5:30 PM | 422 | Effects of Live-Online Education on Multiple Sclerosis Disease Management: Changes in Patient Experience, Clinical Practice, Provider Knowledge and Competence |
Anne Roc, PhD Disclosure: Dr. Roc has nothing to disclose.
|
5:30 PM | 423 | Cognitive reserve is consistently related to cognitive performance in Multiple Sclerosis |
Alvino Bisecco Disclosure: Dr. Bisecco has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Merck.
|
5:30 PM | 424 | Impact of Multiple Sclerosis on Employment and its Association with Anxiety, Depression, Fatigue and Sleep Disorders |
Edgar Carnero Contentti Disclosure: Dr. Carnero has nothing to disclose.
|
5:30 PM | 425 | NA |
NA NA Disclosure:
|
5:30 PM | 426 | NA |
NA NA Disclosure:
|
5:30 PM | 427 | NA |
NA NA Disclosure:
|
5:30 PM | 428 | NA |
NA NA Disclosure:
|
Neuropathy II | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 429 | Skin coldness and painful cold: the common symptom in patients with clinically suspected small fiber neuropathy in Korea |
Eun Bin Cho, MD Disclosure: Dr. Cho has nothing to disclose.
|
5:30 PM | 430 | Is There A Relationship Between Exacerbated Diabetic Peripheral Neuropathy And Metformin? |
Mohammed El-Sherif, MD Disclosure: Dr. El-Sherif has nothing to disclose.
|
5:30 PM | 431 | Brachial plexopathy after influenza vaccination in adults in the USA. A report from the CDC/FDA Vaccine Adverse Event Reporting System (1990-2017) |
Shreya Shah Disclosure: Dr. Shah has nothing to disclose.
|
5:30 PM | 432 | Neuropathy with Dysarthria and Ophthalmoparesis |
Tekalign Burka, MD Disclosure: Dr. Burka has nothing to disclose.
|
5:30 PM | 433 | Use of Intravenous Immunoglobulin in Small Fiber Neuropathy associated with FGFR3 |
Ajal Dave, MD Disclosure: Dr. Dave has nothing to disclose.
|
5:30 PM | 434 | Isolated external ophthalmoplegia associated with IgG anti-GQ1b antibody |
Sunhee Kim, MD Disclosure: Dr. Kim has nothing to disclose.
|
5:30 PM | 435 | A case of remission from multifocal motor neuropathy following rituximab |
Natalia Gonzalez, MD Disclosure: Dr. Gonzalez has nothing to disclose.
|
5:30 PM | 436 | Late Onset TTR-related Familial Amyloid Polyneuropathy (FAP) in Two Patients with Acquired Demyelinating Features |
Nazila Rad, MD Disclosure: Dr. Rad has nothing to disclose.
|
5:30 PM | 437 | A Novel Report of Nivolumab-Induced Parsonage-Turner Syndrome Associated with Hourglass-like Constriction of the Anterior Interosseous Nerve |
Michael Porambo Disclosure: Dr. Porambo has nothing to disclose.
|
5:30 PM | 438 | Acute Intermittent Porphyria: Sometimes DIfficult to Diagnose |
Yuri Macedo, MD Disclosure: Dr. Macedo has nothing to disclose.
|
5:30 PM | 439 | Ganglioside Antibodies in Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) and its Variants |
Mithila Fadia, MBBS Disclosure: Dr. Fadia has nothing to disclose.
|
5:30 PM | 440 | Cognitive Biases at Bedside Resulting in Diagnostic Error of Guillain-Barré Syndrome |
Rohit Gummi Disclosure: Dr. Gummi has nothing to disclose.
|
5:30 PM | 441 | Heterozygous Mutations of SH3TC2 as a Cause of HNPP |
Devin Prior, MD Disclosure: Dr. Prior has nothing to disclose.
|
5:30 PM | 442 | Reduction in Idiopathic Peripheral Neuropathy Diagnoses Using a Comprehensive EMR-based Laboratory Order Set |
Fang Bai, MD Disclosure: Dr. Bai has nothing to disclose.
|
5:30 PM | 443 | Brachial Plexopathy Post Transcatheter Arterial Chemoembolization |
Kavneet Kaur, MD Disclosure: Dr. Kaur has nothing to disclose.
|
5:30 PM | 444 | Novel Mutation in KIF5A Causing Hereditary Spastic Paraplegia with Axonal Sensorimotor Neuropathy |
Mathieu Cuchanski, DO Disclosure: Dr. Cuchanski has nothing to disclose.
|
5:30 PM | 445 | Eosinophilic Vasculitic Neuropathy As A Presentation Of Churg-Strauss Syndrome |
Sandeep Devarapalli, MD Disclosure: Dr. Devarapalli has nothing to disclose.
|
5:30 PM | 446 | Outcome comparison of mechanically ventilated Guillain-Barre Syndrome versus Myasthenia Gravis in US Hospitals |
Anantha Vellipuram Disclosure: Dr. Vellipuram has nothing to disclose.
|
5:30 PM | 447 | Guillain-Barre Syndrome as a Rare Initial Presentation of Systemic Lupus Erythematosus. |
Swathy Chandrashekhar, MD Disclosure: Dr. Chandrashekhar has nothing to disclose.
|
5:30 PM | 448 | Rapidly Progressive POEMS Syndrome with Absent M protein in Serum or Urine, Normal Bone Survey, and Normal Non-targeted Bone Marrow Biopsy |
Payam Soltanzadeh, MD Disclosure: Dr. Soltanzadeh has nothing to disclose.
|
5:30 PM | 449 | Modifying Hyperglycemic Peripheral Nerve Injury |
Mark Stecker, MD Disclosure: Dr. Stecker has received royalty, license fees, or contractual rights payments from UPTODate.
|
5:30 PM | 450 | Rare Case of Ulnar Neuropathy |
Anai Hamasaki, MD Disclosure: Dr. Hamasaki has nothing to disclose.
|
5:30 PM | 451 | Ustekinumab related CIDP in a patient with psoriatic arthritis |
Gamaleldin Osman, MD Disclosure: Dr. Osman has nothing to disclose.
|
5:30 PM | 452 | Proximal Motor Sensory Hereditary Neuropathy (HMSN-P) in a Peruvian Family with Japanese Ancestry |
Elison Sarapura-Castro, MD Disclosure: Dr. Sarapura Castro has nothing to disclose.
|
5:30 PM | 453 | Acute Motor Axonal Neuropathy (AMAN) presenting with truncal and appendicular ataxia |
Ashmanie Mahatoo, MD Disclosure: Dr. Mahatoo has nothing to disclose.
|
Neuromuscular Diagnostics, Genetics, and Biomarkers | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 454 | Needle Impedance-Electromyography (I-EMG): a New Technique for the Electrodiagnostic Laboratory |
Seward Rutkove, MD Disclosure: Dr. Rutkove has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Myolex, Biogen, Axcella Health, and Merck. Dr. Rutkove has received personal compensation in an editorial capacity for Annals of Neurology. Dr. Rutkove has received compensation for serving on the Board of Directors of Myolex, Inc.. Dr. Rutkove holds stock and/or stock options in Myolex, Inc.. Dr. Rutkove has received research support from Flex-Pharma, Inc..
|
5:30 PM | 455 | Feasibility and Validation of Modified Oculobulbar Facial Respiratory Score (mOBFRS) in Amyotrophic Lateral Sclerosis |
Marie Wencel, CCRP Disclosure: Dr. Wencel has nothing to disclose.
|
5:30 PM | 456 | A New Method to Detect Potential Causative Genes for Spastic Paraplegia Utilizing Aggregate Data of Whole Exome Sequencing |
Masaki Tanaka Disclosure: Dr. Tanaka has nothing to disclose.
|
5:30 PM | 457 | Smart Somatotopic Quantitative Sensory Testing findings in hATTR with Polyneuropathy |
Marcus Vinicius Pinto Disclosure: Dr. Pinto has nothing to disclose.
|
5:30 PM | 458 | Genetics in patients with hereditary neuropathy |
Ernesto Alonso-Labori, MD Disclosure: Dr. Alonso-Labori has nothing to disclose.
|
5:30 PM | 459 | Correlation of supranormal sensory nerve action potential amplitudes (supraSNAPs) with sensory nerve "hyperexcitable" symptoms |
Philip Tipton, MD Disclosure: Dr. Tipton has nothing to disclose.
|
5:30 PM | 460 | The Role of Needle Electromyography in the Evaluation of Carpal Tunnel Syndrome |
Cory Kogelschatz, MD Disclosure: Dr. Kogelschatz has nothing to disclose.
|
5:30 PM | 461 | Morphometry of dorsal rootlets using immunofluorescent confocal microscopy |
Adam Loavenbruck, MD Disclosure: Dr. Loavenbruck has nothing to disclose.
|
5:30 PM | 462 | Utility of Neuromuscular Ultrasound in the Evaluation of Proximal Median Neuropathies: A Case Series |
Elina Zakin Disclosure: Dr. Zakin has nothing to disclose.
|
5:30 PM | 463 | Why do we repeat electrodiagnostic studies? And, does it make a difference? |
Shivakrishna Kovi Disclosure: Dr. Kovi has nothing to disclose.
|
5:30 PM | 464 | Ultrasound Guided Open Muscle Biopsy |
Shumaila Sultan, MD Disclosure: Dr. Sultan has nothing to disclose.
|
5:30 PM | 465 | Clinic and Lab Based Respiratory Testing in Patients with Myasthenia Gravis |
Hans Katzberg, MD Disclosure: Dr. Katzberg has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with CSL Behring and Octapharma. Dr. Katzberg has received research support from Octapharma.
|
5:30 PM | 466 | Comparison of Train of Four with Repetitive Nerve Stimulation in the ICU |
Omer Suhaib, MD, MBBS Disclosure: Dr. Suhaib has nothing to disclose.
|
5:30 PM | 467 | Should We Refer Patients with Pain for Electromyography? |
Shivkumar Bhadola Disclosure: Dr. Bhadola has nothing to disclose.
|
Medical Student Essay Award Recipients | |||
Start Time | Pub. | Title | Presenter |
5:30 PM | 468 | Functional neurological disorders in Parkinson disease |
Benjamin Wissel Disclosure:
|
5:30 PM | 469 | Ghost in the Machine: Historical Aspects of Irreversible Brain Injury and Brain Death |
Yi Tong Disclosure: Dr. Tong has nothing to disclose.
|
5:30 PM | 470 | Discovery of novel recessive genes in a consanguineous cohort using genotype-phenotype correlations |
Kristen Martin Disclosure: Dr Martin has nothing to disclose.
|